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Abstract 
Interventions to reduce the burden of dementia-causing diseases are urgently 
needed given global ageing, and the current lack of effective therapeutic approaches. 
Alzheimer’s disease (AD) is a neurodegenerative disease, and the most common cause 
of dementia among older people, for which there is no known cure, or effective 
treatment. Engagement in complex cognitive activity can promote an array of 
neuroplastic mechanisms associated with cognitive protection. Epidemiological 
evidence suggests a high level of cognitive engagement, particularly in early-life, to be 
associated with a reduced risk of developing dementia in later-life, including that 
caused by AD. However, an intervention aimed at preventing or delaying dementia is 
more likely to be taken up in later-life. Furthermore, limitations inherent in 
epidemiological investigations means that the mechanisms underlying this putative 
relationship are not well understood, and the array of extraneous factors that are 
encountered over a person’s life-span cannot be controlled for.  
In the current study, an environmental enrichment (EE) paradigm was used, in 
order to experimentally recapitulate the promotion of neural plasticity from experience. 
The overarching aim of this study was to investigate the effect of EE in healthy ageing, 
and on AD-associated pathological ageing after the onset of disease-induced pathology, 
following a non-stimulating early-life. Healthy wildtype (Wt) and transgenic AD 
(APPSWEPS1dE9) mice were raised in a non-stimulating environment (standard housing; 
SH) and then randomly assigned back into SH or into EE starting at mid-life (6 months) 
or later-life (12 months) for a 6-month period. Further, it was aimed to: assess the effect 
of mid-life EE on hallmark AD neuropathological and structural brain alterations, and 
how this related to cognitive features, and how this differed to healthy ageing; to 
investigate the effect of a complex and novel EE paradigm (EE+) on Aβ 
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neuropathology; and to examine whether the brains’ immune cells, microglia, have a 
role in the link between EE and cognitive protection in a late-life intervention.  
The key conclusions drawn from these investigations were that mid-life and 
later-life EE were not effective interventions in reducing Aβ pathological burden in the 
presence of existing pathology. However, the mid-life EE paradigm was associated with 
compensatory processes in AD mice, demonstrated by a benefit to short-term memory, 
an increase in the neurotrophin BDNF in the hippocampus, and an increase in synaptic 
density in the CA1 subregion of the hippocampus. The EE+ paradigm was introduced 
to assess whether more complex activity would be associated with reduction to Aβ 
pathological burden. Conversely, following the complex and novel paradigm in mid-
life, AD mice developed exacerbated Aβ neuropathological burden, and demonstrated 
an increased vulnerability to stress. APP/PS1 mice were found to have an increase in 
the area occupied by microglia in the hippocampus and neocortex relative to healthy 
ageing Wt mice, however, late-life EE altered this effect, resulting in no genotype 
differences. Overall, this investigation demonstrated EE paradigms introduced through 
mid to later-life for both non-pathological and pathological ageing, are associated with 
some level of cognitive enhancement. The findings of this thesis suggest the protective 
effect of EE on cognitive function in a transgenic model of AD pathology, relies on an 
enhancement of synaptic connectivity and factors that promote neural plasticity, as 
cognitive protection was observed with no evidence of an attenuation of existing Aβ 
neuropathology. 
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1. Introduction 
 
Neural plasticity describes the capacity of neurons and neural circuits to 
undergo structural and functional alterations in response to experience. Over the late 
19th century, the view of the adult brain being a fixed entity was replaced by the now 
prevailing view of the adult nervous system being highly adaptive, and capable of 
exhibiting plasticity well past the sensitive “critical periods” during early development 
(Fuchs & Flügge, 2014). However, there is evidence that we have long been aware of 
the effect of experience from the environment on the neural system, with the idea that a 
lack of stimulation would cause neural processes to withdraw from each other posited 
as early as the 19th century (Bain, 1872; Cajal, 1894; as cited in Rosenzweig, 1996). In 
a time of population ageing, with a concomitant higher vulnerability to 
neurodegenerative disease and cognitive deterioration, it is critical to understand how to 
harness and promote neural communication and enhance the plastic capacity of the 
ageing nervous system. 
The global ageing of populations is driving a substantial increase in the presence 
of dementia. Dementia describes a syndrome in which there is a progressive loss of 
memory, cognition, changes to behaviour, and an impaired ability to perform everyday 
activities (Sosa-Ortiz, Acosta-Castillo, & Prince, 2012). Although once thought to be an 
inevitable part of ageing, it is possible to experience ageing without dementia. 
However, with age, the nervous system becomes increasingly vulnerable to conditions 
that cause dementia (Hofer, Berg, & Era, 2003). Ageing can occur non-pathologically, 
accompanied by “normal” ageing-related decline, as opposed to pathological-induced 
decline observed in diseases such as Alzheimer’s disease (AD; Hedden & Gabrieli, 
2004). Normal cognitive ageing is heterogeneous, however, there is a typical pattern of 
decline to processing speed, episodic and working memory, while short-term and 
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autobiographical memory, semantic knowledge, and emotional processing typically 
remain stable (Hedden & Gabrieli, 2004; Salthouse, 2011). Observed in those with 
dementia, is earlier memory impairment, followed by incipient global cognitive decline 
(Weintraub, Wicklund, & Salmon, 2012). While more constrained in later life, the brain 
has capacity to alter its structure and function over the entire lifespan (Jellinger & 
Attems, 2013). Why differing trajectories to normal cognitive ageing, or a decline into 
pathological cognitive ageing are experienced is not well understood, however, a 
complex interaction of biology and the environment is likely. 
 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD), clinically described as an ultimate progression of 
global cognitive and behavioural impairment, the disease has no current effective 
treatment or cure (Prince et al., 2015). AD is the most common cause of dementia, and 
is also one of the mostly widely studied forms of neurodegenerative disease (Hardy, 
1997; Vickers et al., 2000). It was over a century ago that Alois Alzheimer first detailed 
the clinical expression of the disease in his patient Auguste D, and further described the 
presence of abnormal structures within the brain tissue. Despite concerted research 
efforts over the last century, there is no clear understanding of the fundamental 
underlying pathological processes of the disease and how this is related to the clinical 
outcome of dementia. 
 The pathological interpretation of AD focuses on the presence of the abnormal 
structures as detailed by Alzheimer, described as the pathological hallmarks of the 
disease. Held in the extracellular space of an AD brain, are fine filaments composed of 
β-amyloid (Aβ) that accumulate to form plaques. Observed in cell bodies are aggregates 
of abnormally hyperphosphorylated and aberrantly misfolded tau that comprise 
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neurofibrillary tangles (Vickers et al., 2000; Woodhouse, Vickers, Adlard, & Dickson, 
2009). While Aβ plaques and neurofibrillary tangles are named as hallmarks of the 
disease, there is a wealth of inconsistent reports relating these as normal features to the 
clinical expression of AD (e.g. Arriagada, Growdon, Hedleywhyte, & Hyman, 1992; 
Berg et al., 1998; Giannakopoulos et al., 2003). The discrepancy between the severity 
of AD-associated neuropathology and its clinical expression has been a source of 
discussion in the literature (e.g. Nelson, Braak, & Markesbery, 2009; Jagust, 2016).  
The connectivity of the neural system is widely thought to be the substrate of 
cognitive function. A loss on connectivity, through the loss of synapses particularly in 
the frontal and temporal cortex, is thought to be an early event in AD pathogenesis, and 
to be the strongest neurobiological correlate of cognitive dysfunction in AD (DeKosky 
& Scheff, 1990; Terry et al., 1991; Scheff & Price, 2006; Scheff, Price, Schmitt, 
Dekosky, & Mufson, 2007; Arendt, 2009). Evidence of synaptic dysfunction and loss 
being closely linked with the clinical expression of AD also gives rise to the idea that 
the synapse should be the focus of therapeutics. However, given synapse loss is 
particularly apparent within or surrounding fibrillar Aβ plaques in both human cases 
and in transgenic mouse models (Masliah et al., 1994; Sze et al., 1997; Hu, Wong, 
Côté, Bell, & Cuello, 2003; Dong, Martin, Chambers, & Csernansky, 2007), leads to 
the hypothesis of Aβ being a driving force of synaptic loss and subsequent cognitive 
dysfunction in AD. 
 
1.1.2 Animal models of Alzheimer’s disease 
Transgenic animal models that exhibit the cardinal features of AD are at the 
forefront of insight gained into the disease. A considerable degree of molecular 
understanding of AD has come from studying familial AD (FAD)-linked mutations, 
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namely the APP, PS1 genes that encode the amyloid precursor protein and presenilin 1. 
Many transgenic mouse models used to study the pathogenesis of AD utilize these FAD 
mutations, which lead to amyloid pathology and memory impairment (Puzzo, Gulisano, 
Palmeri, & Arancio, 2015). Mouse models with APP and PS1 mutations are considered 
an early-stage AD model, and do not develop the second major pathological feature of 
AD, neurofibrillary tangles (Garcia-Alloza et al., 2006). 
 
1.1.3 Amyloid pathology 
It is widely believed that Aβ is central to the pathogenesis of AD. In this regard, 
the ‘amyloid cascade hypothesis’ proposes that AD is initiated by an imbalance 
between the production and clearance of Aβ (Hardy & Selkoe, 2002). The Aβ peptide is 
derived from the proteolytic cleavage of APP. APP is processed by non-amyloidogenic 
or amyloidogenic pathways. APP is delivered to the surface membrane where it is 
cleaved by a-secretase. APP molecules not cleaved by a-secretase can be internalised 
into endocytic compartments and cleaved by β-secretase then g-secretase to generate Aβ 
(O’Brien & Wong, 2011). The most abundant form of Aβ is the Aβ40 species, however, 
the Aβ42 species has a greater propensity to aggregate into the Aβ plaques characteristic 
of AD (Thal, Walter, Saido, & Fändrich, 2015). There is some contention in the 
literature on the association between the presence of Aβ neuropathology and the clinical 
expression of dementia. A study utilising PET-amyloid imaging led to the detection of 
Aβ deposition correlating with episodic memory decline, one of the main clinical 
features of AD (Villemagne et al., 2013). However, a meta-analysis including 3000 
cognitively normal subjects reported the strength of this relationship to be small 
(Hedden, Oh, Younger, & Patel, 2013).  
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1.2 Brain and Cognitive reserve  
 
In the classic study by Katzman et al. (1989), it was reported through post-
mortem examination, that some people with AD-like neuropathology had no clinical 
phenotype of the disease before death. This pioneering finding led the authors to 
postulate that neuropathological burden does not necessarily directly correlate with 
cognitive outcome. In order to explain the possible disconnect between Aβ pathology 
and clinical expression of the disease, it was hypothesized that there may be a brain 
reserve that allows one to function at a non-impaired level despite the presence of 
neuropathology (Satz et al., 1993). The concept of brain reserve is hypothetical, 
however, brain size and synapse count are thought to encompass the measurable 
substrate of brain reserve (Satz et al., 1993; Stern, 2002). Katzman et al. (1988) further 
found individuals with intact cognition despite the presence of substantial AD-
associated pathology, also had larger brain weight, offering support that brain reserve 
offers one capacity to cope with pathology. It is further posited that with disease 
process progression, brain reserve capacity is depleted, and once this critical point is 
reached, clinical deficits emerge (Satz, 1993).   
The cognitive reserve theory proposes the brain has the capacity to actively cope 
with pathological damage in order to preserve cognitive function (Stern, 2002). The 
theory as applied to AD suggests that pathological damage to the brain can be offset by 
the use of pre-determined cognitive strategies and the efficient use, or differential 
recruitment, of neural networks (Stern, 2002; 2012). That is, people who engage in 
higher levels of mental activity develop stronger, more elaborated, and more efficient 
neuronal networks, allowing them to withstand a greater degree of pathological burden 
before clinical expression of the disease emerges. 
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1.3 Can plasticity be promoted to offset dementia? 
 
Plasticity is not only a substrate of cognition, the brain’s plastic capacity also 
allows it to compensate for neuronal insult (Jellinger & Attems, 2013), such as that 
encountered by AD. Promoting plasticity in ageing may therefore assist the neural 
system in coping with ageing-related pathological alterations. Epidemiological evidence 
suggests cognitive activity may act in the promotion of neural plasticity, and have a 
protective role against dementing conditions. 
There is a putative link between education and dementia, an association 
pioneered by Mortimor (1988; Sharp & Gatz, 2011). Several studies have offered 
support for this association over subsequent years. In studies of catholic clergy, 
education was found modulate the expression of dementia due to AD, where those more 
highly educated withstood a greater amount of neuropathology before AD manifested 
clinically (Bennett et al., 2003). Further evidence suggests that it is not only formal 
education that mediates dementia risk, but various components of cognitive lifestyle. A 
systematic review of 22 longitudinal cohort studies reported a highly cognitively 
engaged lifestyle, which encompassed high levels of education, occupation, and 
engagement in other forms of complex cognitive activity, was associated with a 46% 
lower dementia risk than those who had a minimally active cognitive lifestyle 
(Valenzuela & Sachdev, 2006). In addition, engagement in leisure and physical activity 
has been reported to offer protection against ageing-associated cognitive decline 
(Friedland et al., 2001; Scarmeas, Levy, Tang, Manly, & Stern, 2001; Wang et al., 
2013; Kamegaya, Araki, Kigure, & Yamaguchi, 2014; Marioni et al., 2015). Together, 
this evidence has offered support for a stimulating lifestyle to have a fundamental role 
in healthy brain ageing. 
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Based on such epidemiological evidence, there is considerable and growing 
interest in the capacity of the central nervous system (CNS) to protect against, or 
compensate for pathological damage of the brain associated with AD. Although the 
epidemiological evidence is showing promise, the extent to which cognitive activity 
may build reserve and protect against AD or ageing-associated cognitive decline is 
difficult to determine from such studies, primarily because the effect of cognitive 
activity cannot be isolated from various other lifestyle factors. Moreover, the 
underlying neural mechanisms that may allow for this protection can rarely be 
investigated in human populations.  
 
1.4 Environmental enrichment 
 
Environmental enrichment (EE) is a paradigm applied to animal models, in 
order to experimentally model the promotion of neural plasticity from experience. The 
paradigm involves the manipulation of an animals’ environment, aimed at encouraging 
environmental stimulation with objects designed to generate physical, sensory, and 
cognitive activity. The paradigm is used to study how experience from the environment 
influences the development, refinement, and maintenance of the neural system. The 
earliest studies starting in the 1960’s reported changes in the neuroanatomy of the 
healthy rodent brain following exposure to EE, including increased cortical thickness 
(van Praag, Kempermann, & Gage, 2000). Heightened brain connectivity and markers 
of plasticity were subsequently reported, in which increased dendritic branching, spine 
density, and synaptic contacts have been observed in EE exposed rodents (Greenough, 
Volkmar, & Juraska, 1973; Connor, Wang, & Diamond, 1982; Leggio et al., 2005). 
Living in a stimulating environment has been demonstrated to promote an array of 
morphological and molecular changes within the healthy CNS that are thought to 
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modify behaviour and heighten cognitive function compared to animals housed in 
standard housing (SH; Segovia, del Arco, & Mora, 2009). 
 
1.4.1 Environmental enrichment as an intervention for AD  
 
Given the range of beneficial effects on the structure and function of the nervous 
system in healthy animal models, the EE paradigm has been applied to animal models 
of neuropathology. Transgenic FAD animal models allow for the study of the effect of 
stimulation from the environment, EE, on the pathological, cognitive, and behavioural 
alterations observed in the disease.  
A potentially pivotal study by Kamenetz et al. (2003) led to the suggestion that 
cognitive stimulation may affect the biochemistry of AD. In organotypic hippocampal 
slice cultures from transgenic mice harbouring the APP mutation, neuronal activity was 
found to bi-directionally control Aβ levels. Blocking neuronal activity by a GABA-A 
receptor potentiator resulted in a reduction of Aβ levels, whilst inducing neuronal 
activity with a GABA-A channel blocker, led to an increase in Aβ. The study also 
demonstrated a modulation of synaptic plasticity following manipulation of neuronal 
activity. A global down-regulation of excitatory synapses was reported following a 
decrease in neuronal activity, and an increase in neuronal activity up-regulated 
excitatory synapses. The finding that neuronal activity can regulate APP processing, 
and thus Aβ production has led to the hypothesis that cognitive stimulation may affect 
AD pathology by influencing neuronal proteins implicated in the disease (Wang, 
Megill, He, Kirkwood, & Lee, 2012). 
 Following this finding, Jankowsky, Xu, Fromholt, Gonzales, & Borchelt, 
(2003) proposed to model a functional change in synaptic activity in-vivo. In this study, 
an EE paradigm was employed in order to promote neuronal activity, and the 
subsequent effects on Aβ pathology in a APP/PS1 mouse model was assessed. Female 
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mice were placed into EE at an early, pre-symptomatic stage of the disease. Paradoxical 
to the reported beneficial effects of EE found in healthy rodents, and to that of in-vitro 
studies, the authors reported a higher plaque burden in EE-exposed APP/PS1 mice, yet 
increased cognitive function. The authors suggested higher levels of cognitive 
stimulation accelerates amyloid pathology, but compensatory mechanisms brought 
about by enhanced brain function may mitigate the effects of pathology. Despite the 
counterintuitive findings, the authors demonstrated that amyloid pathology in an AD 
mouse model to be altered in response to experience from the environment. 
Since the initial study by Jankowsky and colleagues (2003) a number of 
investigations on the effect of EE on a range of transgenic AD mouse models have been 
performed. Arendash et al. (2004) approached the enrichment paradigm for an APP 
mouse model therapeutically by starting EE at an advanced stage of AD pathology, 
rather than preventatively, or before the onset of Aβ pathology, as did Jankowsky and 
co-workers (2003). Mice with the human APP mutation were entered into EE at an 
advanced stage of AD at 16 months of age. These mice lived in a constantly enriched 
environment for four months, and were exposed to a novel environment weekly. At 22 
months of age, EE mice performed superiorly on a battery of cognitive testing 
procedures when compared to mice housed in standard housing. However, these 
cognitive improvements were independent to that of Aβ load. Total Aβ load in the 
parietal cortex and hippocampus were of a moderate level regardless of housing 
condition. The authors concluded in partial agreement with Jankowsky et al. (2003), 
that the behavioural benefits of EE to AD may involve a separate mechanism to that of 
abnormal Aβ processing and deposition. The findings of the two studies highlight the 
ambiguous association of Aβ deposition and the clinical expression of the disease. 
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Lazarov et al. (2005) hypothesised a decrease in Aβ pathology could occur in 
response to the environment, if an enriched “experience” was introduced in early life. 
At weaning, male APP/PS1 mice were exposed to EE for five months. Lazarov and 
colleagues observed a dramatic reduction in Aβ deposition in the neocortex and 
hippocampus of EE mice compared to that of SH mice. One particularly noteworthy 
finding of the study was that Aβ burden was inversely correlated with physical activity 
(time spent on the running wheel). Lazarov et al. further demonstrated that the activity 
of the Aβ degrading enzyme, neprilysin, was elevated in the brains of EE AD mice 
compared to WT, and AD SH mice. The authors suggested their remarkably different 
findings from that of Jankowsky and co-workers (2003) could be due to sex of the 
subjects, as female mice were employed for this study, which have a higher amyloid 
burden than age-matched males (Wang, Tanila, Puoliväli, Kadish, & Van Groen, 2003). 
However, Arendash and colleagues (2004) employed male APP mice, albeit at an older 
age, and did not demonstrate a reduction in pathology. Although conflicting with the 
previous in-vivo studies, Lazarov et al. provided the first experimental evidence that 
exposure to EE reduces Aβ burden. 
Jankowsky et al. (2005) further investigated the effect of EE in female APP/PS1 
mice by housing mice in the EE condition from two months to eight months of age. At 
eight months, cognitive testing revealed EE mice to have significantly better spatial 
memory that SH mice. However, EE mice had a 25% higher Aβ load in comparison to 
SH mice, a result consistent with the earlier 2003 study. The authors suggested a 
sexually dimorphic response to EE might be the reason behind the different 
pathological outcomes to that of Lazarov and co-workers (2005). Moreover, the authors 
put forward that multiple studies have documented human patients to have intact 
cognitive function, despite the presence of Aβ plaques at a level sufficient for an AD 
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diagnosis. Thus, the authors contribute their results to EE working through a 
mechanism independent to Aβ deposition, such as through building cognitive reserve, 
and conclude that the nervous system can be substantially influenced by the 
environment. 
Costa et al. (2007) extended the work from Arendash et al. (2004) to determine 
if EE not only worked as a therapeutic against AD-associated cognitive dysfunction, but 
whether it could protect against cognitive impairment. At weaning, male and female 
APP/PS1 mice were placed into EE or SH for 4.5-5.5 months. Following, half of the 
mice underwent comprehensive behavioural testing, while the other half did not, in 
order to control for the potential enriching effect that behavioural testing may have. 
Enriched mice outperformed SH mice, and there were no differences in performance 
between transgenic EE and healthy wildtype SH mice. The authors suggested that EE 
allowed for cognitive protection in the transgenic AD mice, bringing their cognitive 
function up to the level of the healthy control mice. While non-behaviourally tested 
mice showed no difference in Aβ levels, behaviourally tested EE mice demonstrated 
lower Aβ deposition than non-behaviourally tested mice. The authors suggested 
consistent with the findings of Lazarov et al. (2005) that a more demanding EE 
paradigm, that is EE in combination with behavioural testing, must induce brain 
changes that compensate for the damage brought about by Aβ pathology. 
 
1.4.2 What type of EE paradigm is efficacious in FAD mouse models? 
 
EE paradigms used for FAD animal models do encompass potential 
confounders, such as the use of different FAD models, age and stage of pathology, 
gender, type of EE paradigm, and length of exposure to EE, whether EE is intermittent 
or stable, or includes a novelty component, that might explain the variable findings 
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regarding Aβ burden. The discrepancy in findings on the effect of EE on amyloid 
pathology (Table 1) may be due to the type and intensity of the intervention, as this is 
not controlled for in such studies.  The study raises implications for protecting against 
AD in humans, with evidence provided for a combination of stimulating activities 
offering the greatest protection against AD.  
 
As also demonstrated in Table 1, EE is introduced at different ages in various 
studies, and importantly with varying stages of pathology. While previous 
investigations focused on starting enrichment at an early, pre-symptomatic age and 
lasting over disease progression, Herring et al. (2011) set out to examine the effects of 
living in EE only before, or after AD onset. Female mice harbouring the APP mutation 
were entered into EE either prior to disease onset and entered back into standard cages 
thereafter, or lived in SH until disease onset and the transferred to EE. Both preventive 
and therapeutic strategies reduced total Aβ plaque area in these mice. The authors 
concluded that stimulation delivered either before or after disease onset can reduce Aβ 
pathology.
 Verret et al. (2013) reported a reduction in Aβ burden following EE that started 
in early life in a FAD mouse model. However, mice exposed to EE later in life and 
following the deposition of Aβ, the intervention had no effect on Aβ load. These 
findings might suggest that an intervention initiated before the onset of amyloid-
deposition may slow amyloidosis, however, once pathology has progressed, EE has 
little effect on Aβ disease process progression.  
As AD is a ‘silent’ disease for many years before clinical expression and 
subsequent diagnosis (Price & Morris, 1999; Morris et al., 2001), it is important to 
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investigate interventions targeted at late-life prevention of dementia when an 
intervention is more likely to be taken up, or to act therapeutically in people living with 
dementia when it is clear intervention is warranted. Although evidence suggests that 
after disease onset it is too late to alter Aβ pathology (Verret et al., 2013), there is 
evidence to suggest that cognitive protection may be afforded by EE by amyloid-
independent mechanisms. 
 
1.4.3 Stress as a potential confounder 
 
There is evidence of an association between stress and Aβ pathology, which 
may play a role in confounding the link between EE and Aβ. The finding of 
exacerbated Aβ pathology by Jankowsky et al. (2003; 2005) has been suggested to be a 
result of the EE paradigm inducing stress. These animals did have improved cognitive 
function despite increased Aβ burden. There is some evidence that mild stressors result 
in greater capacity of resource management in challenging environmental conditions 
(Crofton, Zhang, & Green, 2015). The idea that such a stressor not only exerts negative 
effects, may explain the finding of superior cognitive function and exacerbated Aβ 
pathology in mice reared in EE. In contrast, Jeong et al. (2011) exposed FAD mice to a 
stress and EE paradigm, and found that  EE counteracted the negative effects of stress 
on AD disease process progression. Given the highly variable findings of EE on Aβ 
pathology, and evidence that stress plays a major role in disease onset and progression, 
it is important to investigate the effects of heightened stimulation on stress, and 
consider how it may moderate the relationship between EE, cognition, and pathology. 
Experiencing a stressful stimulus induces activation of the hypothalamic-
pituitary-adrenal (HPA) axis, leading to a release of glucocorticoids from the adrenal 
cortex. Evidence of HPA axis dysfunction in AD comes from the finding that people 
	 31	
living with AD typically have increased blood levels of the stress hormone cortisol 
(Rasmuson et al., 2001; Csernansky et al., 2006). Elevated levels of the glucocorticoid 
(corticosterone in rodents) has also been reported in a FAD mouse model (Guo, Zheng, 
& Justice, 2012). However, whether chronic stress and subsequent elevated cortisol 
increases risk of developing AD, or whether increased cortisol is a symptom of AD, is 
unknown.  
The mechanisms underlying the finding of an association between elevated 
stress hormone and AD have been explored in FAD rodent models. Green, Billings, 
Roozendaal, McGaugh, and LaFerla (2006) reported in a FAD mouse model, that Aβ 
pathology preceded HPA axis dysfunction. Green and colleagues speculated damage to 
the hippocampus by Aβ plaques would lead to disinhibition of the HPA axis. 
Disinhibition of the HPA axis would lead to an abnormal stress response to aversive 
stimuli, and a subsequent increase in corticosterone. The increasing levels of 
glucocorticoid may further accelerate pathological processes, acting as a cycle of 
disease process progression. Alternatively, it is argued that HPA axis dysfunction 
precedes the formation of extracellular plaques (Rothman et al., 2012). Rothman and 
co-workers found an increase in Aβ oligomers following a 6-week chronic stress 
paradigm in a FAD mouse model. FAD mice not exposed to the stress paradigm also 
had increased basal corticosterone levels despite lower levels of Aβ relative to mice 
exposed to stress. These data suggest HPA axis dysfunction precedes Aβ plaque 
pathology, which may suggest that chronic stress and increased cortisol is associated 
with the development of AD. Whether elevated glucocorticoids precede Aβ pathology, 
or whether it is a symptom of pathology, the effect of EE on stress is a confounding 
factor that is seldom investigated. 
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1.4.4 EE and amyloid-independent cognitive protection 
 
Studies focused on the association between EE and amyloid pathology have also 
led to findings regarding amyloid-independent effects. Arendash et al. (2004) reported 
global cognitive protection in ageing FAD mice exposed to EE, despite no reductions in 
Aβ deposition. Similarly, Jankowsky et al. (2005) reported a counterintuitive increase 
in Aβ pathology, yet a marked attenuation of cognitive dysfunction in FAD mice 
exposed to EE. These findings together might suggest EE may not directly exert its 
affects by mitigating Aβ pathology. EE may build cognitive reserve capacity, allowing 
for cognitive protection despite pathological brain lesions. EE may exert its effects 
through alternative neural mechanisms, that are currently elusive. An understanding of 
these underlying neural mechanisms will likely be invaluable in developing 
therapeutics to delay or halt the onset of dementia. 
 
1.4.5 EE as a means of promoting synaptic plasticity in AD 
 
Synapse loss is currently the strongest neurobiological correlate of cognitive 
dysfunction in AD (DeKosky & Scheff, 1990; Terry et al., 1991; Scheff & Price, 2006; 
Scheff, Price, Schmitt, Dekosky, & Mufson, 2007; Arendt, 2009). Evidence of synaptic 
dysfunction and loss being closely linked with the clinical expression of AD also gives 
rise to the idea that the synapse should be the focus of therapeutics. AD is insidious, yet 
a slowly progressing disease, emerging clinically many years after disease process 
inception (Price & Morris, 1999; Morris et al., 2001). It is conceivable that the process 
of synaptic degeneration is also a slow-acting process, and there may be a point at 
which the degeneration of synapses can be rescued. Concurrently, the nervous system 
has remarkable capacity for plasticity; axons can reinnervate CNS sites and create new 
synapses (Coleman, Federoff, & Kurlan, 2004). The plasticity of the synaptic system 
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might be drawn upon when the brain is infested by AD-related neuropathology to stave 
off, or slow the progression of cognitive dysfunction. While synaptic plasticity is 
perturbed in AD (Chapman et al., 1999; Ma & Klann, 2012; Sorrentino, Iuliano, 
Polverino, Jacini, & Sorrentino, 2014), stimulation from the environment may create 
heightened capacity for plasticity and subsequent compensation for pathological 
damage allowing for cognitive maintenance. 
A number of studies performed on healthy wildtype rodents have demonstrated 
a spectrum of synaptic alterations following EE. Postsynaptic changes have been 
observed through the analysis of dendritic spines in the cerebral cortex and 
hippocampus, in which spine densities were increased by EE (e.g. Turner & 
Greenough, 1985; Rampon et al., 2000; Kolb, Gibb, & Gorny, 2003; Gelfo, De Bartolo, 
Giovine, Petrosini, & Leggio, 2009). Jung and Herms (2014) using in vivo microscopy, 
demonstrated increases in density and turnover of dendritic spines in enriched mice. 
Presynaptic alterations following EE have also been reported in healthy animals 
(Nithianantharajah, Levis, & Murphy, 2004). However, investigations on synaptic 
alterations following EE in AD mouse models have been more limited. Levi, Jongen-
Relo, Feldon, Roses, & Michaelson, (2003) investigated EE-induced effects on mice 
containing the APOE E3 or E4 allele. APOE E4 is a risk factor polymorphism for AD 
(Verghese, Castellano, & Holtzman, 2011), and animals with this genotype did not 
show cognitive improvement following EE. Moreover, the E3 carrier mice showed not 
only heightened cognitive function compared to those carrying E4, but also increased 
levels of hippocampal nerve growth factor (NGF) and heightened levels of 
synaptophysin. 
Further evidence of EE increasing plasticity was provided by Costa et al. 
(2007). Superior cognitive function was reported in an APP/PS1 mouse model exposed 
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to long-term EE. Dendritic branching defects observed in these transgenic animals were 
not overcome by EE, however, EE was found to induce beneficial changes in gene 
expression related to neuronal plasticity. The authors suggested rather than EE directly 
targeting Aβ pathology, more subtle changes, such as alterations in neuronal plasticity-
related gene expression may offer an explanation for the finding of heightened 
cognitive function in the absence of a reduction in Aβ pathological burden. Herring et 
al. (2011) also provided evidence for EE up-regulating expression of plasticity-
associated proteins in an APP mouse model. The authors demonstrated transgenic AD 
mice living in an EE to have increased levels of the plasticity-associated protein Arc 
and heightened synaptic density brought up to the level of healthy wildtypes, and 
significantly higher than transgenic mice living in SH. In addition, Lazarov and 
colleagues (2005) demonstrated through microarray analysis, a number of genes 
differentially regulated by EE in a FAD mouse model, with elevated expression of 
genes involved in neurogenesis and neuronal plasticity. 
Catlow et al. (2009), and Mirochnic, Wolf, Staufenbiel, & Kempermann (2009) 
investigated whether the cognitive protection observed in rodents that underwent EE in 
previous studies, was afforded by an increase in neurogenesis. Mirochnic et al. 
compared APP mice that lived in either SH, EE, or physical activity housing for adult 
neurogenesis in the hippocampal dentate gyrus at 6 and 18 months. At the 18-month 
time-point, mice living in SH had a higher Aβ1-42/ Aβ1-40 ratio as well as a lower 
number of newborn granule cells in the hippocampus dentate gyrus compared to the EE 
and physical activity housing conditions. Catlow et al. however, also investigated 
neurogenesis in the hippocampal dentate gyrus in APP/PS1 mice and found no 
difference among impoverished, EE, or physical stimulation housing conditions. The 
authors concluded that the generation of new neurons in the hippocampal dentate gyrus 
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is not involved with cognitive protection following EE. Mirochnic and colleagues’ 
findings on the other hand suggested that enrichment is effective in increasing adult 
hippocampal neurogenesis, and perhaps aids in protecting cognitive function. 
 
1.4.6 EE, AD, and brain-derived neurotrophic factor 
 
Alterations in neurotrophins, such as brain-derived neurotrophic factor (BDNF), 
may provide one underlying mechanism of the association between EE and cognitive 
benefit in FAD models. BDNF is a nerve growth factor expressed throughout the CNS, 
and is vital for the maintenance, survival and growth of neurons (Mattson, Maudsley, & 
Martin, 2004). In addition, BDNF promotes neuronal survival, neurite growth, and 
synthesis of neurotransmitters and neurogenesis (Barde, Edgar, & Thoenen, 1982). 
Considerable evidence from in vitro and in vivo experimental studies suggests BDNF to 
have pro-survival functions on neurons under different pathological conditions (Lu, 
Nagappan, Guan, Nathan, & Wren, 2013), signifying BDNF may be a key target 
molecule in developing therapeutics for various diseases of neuropathology. 
BDNF has been implicated in AD, with reduced levels of BDNF found in the 
hippocampus and frontal and parietal cortices of the AD brain (Ferrer et al., 1999; 
Hock, Heese, Hulette, Rosenberg, & Otten, 2000). As BDNF mediates synaptic 
plasticity and cognitive function (e.g. Murer, Yan, & Raisman-Vozari, 2001; Lu, 2003; 
Yoshii & Constantine-Paton, 2010), it is thought that BDNF may be critically involved 
in the pathophysiology underlying cognitive decline in AD. BDNF regulates processing 
of APP through the non-amyloidogenic pathway (Fu, Lu, & Mattson, 2002; Rohe et al., 
2009), which may yield beneficial effects, such as a reduction in the production of Aβ 
peptides, and the release of the secreted form of APP, which is associated with 
neuroprotective effects (Scheuner et al., 1996; Nishitomi et al., 2006; Thornton, Vink, 
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Blumbergs, & Van Den Heuvel, 2006). Moreover, studies employing in vitro methods 
have reported a protective effect of BDNF on Aβ42 (Arancibia et al., 2008; Aliaga et al., 
2010).    
Additional evidence that BDNF expression should be promoted in AD comes 
from the increasing view that AD is a disease of synaptic plasticity failure. BDNF 
promotes synapse formation (Park & Poo, 2013), which may be through the promotion 
of dendritic growth (McAllister, Lo, & Katz, 1995), axonal branching (Cohen-Cory & 
Fraser, 1995) and activity-dependent synapse refinement (Cabelli, Hohn, & Shatz, 
1995). Due to evidence of the beneficial effects of BDNF on synaptic plasticity, it is 
also thought to play a critical role in cognitive function. Despite the accumulating 
evidence that therapeutic strategies should target BDNF pharmacologically, to date 
BDNF has not been able to be delivered across the blood-brain barrier (Lu et al., 2013). 
However, some evidence suggests EE may be able to increase endogenous levels of 
BDNF. 
Increases in BDNF expression in the hippocampus of healthy animals 
following EE have been found (Kuzumaki et al., 2011; Ramírez-Rodríguez et al., 
2014; Novkovic, Mittmann, & Manahan-Vaughan, 2015), as well as global increases 
(Ickes et al., 2000). There has been limited work on the relationship between EE and 
BDNF in FAD models. However, Wolf and co-workers (2006) reported in an APP 
reported improved cognitive function following EE, possibly accounted for by an up-
regulation of BDNF. There is a wealth of evidence linking increased BDNF 
expression to physical activity (Erickson, Miller, & Roecklein, 2012), which forms a 
caveat to the EE research in which it is uncertain if it the physical activity along, 
rather than cognitive stimulation, that is driving the increased in BDNF. 
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1.4.7 EE, AD, and microglia 
 
Microglia are the brain’s tissue macrophages, the primary immune effector cells 
in the CNS. Microglia are distributed throughout the brain (Perry, Hume, & Gordon, 
1985; Nimmerjahn, Kirchhoff, & Helmchen, 2005) and constantly survey their 
environment for pathogens, apoptotic cells, and foreign material (Streit, Mrak, & 
Griffin, 2004). Microglia are critically involved in generating chronic, and self-
sustaining neuroinflammation (Rubio-Perez & Morillas-Ruiz, 2012), and current 
evidence suggests neuroinflammation to be key contributor to the pathogenesis of AD 
(Heneka et al., 2015). Evidence suggests that the involvement of neuroinflammation to 
be an early, and substantial process leading to AD pathogenesis, further supported by 
the finding that genes for immune receptors are associated with AD (Bradshaw et al., 
2013; Griciuc et al., 2013; Guerreiro et al., 2013).  
 Originally described by Alzheimer over 100 years ago, there is a characteristic 
increase in microglial activation within the AD brain (Steltzmann, Schitzlein, & 
Murtagh, 1907; as cited in Mosher & Wyss-Coray, 2014). However, it has only been 
more recently that the resident macrophages of the brain have received attention for 
their role in CNS function and dysfunction (Derecki, Katzmarski, Kipnis, & Meyer-
Luehmann, 2014). Microglia frame dense-core Aβ plaques, their recruitment to plaques 
causes a morphologic change, typically thickened, dystrophic processes and increased 
soma size (Itagaki, McGeer, Akiyama, Zhu, & Selkoe, 1989). In the AD brain, 
microglia surrounding amyloid plaques, are observed to have an ‘activated’, pro-
inflammatory phenotype (Perlmutter, Barron, & Chui, 1990). Intriguingly, microglia do 
not surround diffuse Aβ plaques in the “normal” ageing brain (Itagaki et al., 1989; 
Heurtaux et al., 2010; von Bernhardi, 2007).  
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Due to frequent observations of highly reactive, phagocytic microglia 
surrounding Aβ plaques, there are current, extensive research efforts focused on the role 
of microglia in AD pathogenesis. In vivo imaging studies have provided evidence of 
microglia being recruited rapidly to newly formed Aβ plaques, and microglia processes 
remain highly dynamic (Meyer-Luehmann et al., 2008). It is thought that microglia 
surrounding Aβ plaques appear to form a barrier that restricts plaque growth, in order to 
prevent the diffusion of Aβ oligomers that are synaptotoxic (Bolmont et al., 2008; 
Meyer-Luehmann et al., 2008; Condello, Yuan, Schain, & Grutzendler, 2015). 
However, microglia may become dysfunctional after they are recruited to Aβ plaques 
(Krabbe et al., 2013). There is evidence of microglial dysfunction in ageing, which may 
mean microglia are unable to form an effective barrier surrounding plaques. During 
ageing, microglia undergo morphological alterations; they show an increased soma size, 
and processes are shorter, sparse, and dystrophic (Streit, 2006; Flanary, Sammons, 
Nguyen, Walker, & Streit, 2007). These morphological alterations are thought to confer 
functional deficits, as observed in in vivo and in vitro experiments, microglia in ageing 
may be unable to phagocytose Aβ effectively (Floden & Combs, 2011; Sheng, Mrak, & 
Griffin, 1998; Sierra, Gottfried-Blackmore, Mcewen, & Bulloch, 2007), potentially 
providing one explanation for AD being more generally a disease of ageing. 
As discussed previously, AD is a disease of synaptic loss and synaptic plasticity 
failure (DeKosky & Scheff, 1990; Terry et al., 1991; Scheff & Price, 2006; Scheff et 
al., 2007; Arendt, 2009). There is emerging evidence of microglia being critically 
involved in the elimination and refinement of synaptic connections in the healthy brain. 
Microglial processes constantly contact axons, dendritic spines, and synapses (Stevens 
et al., 2007; Paolicelli et al., 2011; Schafer et al., 2012). The dynamics of microglial 
processes have been found to be regulated by sensory experience and neuronal activity 
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(Wake, Moorhouse, Jinno, Kohsaka, & Nabekura, 2009; Tremblay, Lowery, & 
Majewska, 2010), and have also been implicated in learning processes, through their 
interaction with synaptic contacts. A study where microglia were ablated in the adult 
rodent brain, led to an impairment in learning, and an associated reduction in learning-
induced synapse formation in the motor cortex (Parkhurst et al., 2013). These findings 
together suggest microglia to have a role in experience-dependent synaptic plasticity. 
Recent evidence suggests that lifestyle factors such as physical and cognitive 
activity can play a role in promoting microglial health in ageing. In the APP/PS1 FAD 
mouse model, physical exercise was associated with a reduction in both Aβ levels and 
microglial activation (Ke, Huang, Liang, & Hsieh-Li, 2011). There have also been 
reports that the neuronal benefits conferred by EE may occur by modulation of innate 
immune cells, including microglia (Ziv et al., 2006; Choi et al., 2008; Vukovic, Colditz, 
Blackmore, Ruitenberg, & Bartlett, 2012). Moreover, an association between EE and 
the quantity of microglia occupying neocortex and hippocampus has been reported 
(Ehninger & Kempermann, 2003; Williamson, Chao, & Bilbo, 2012; Xu et al., 2016). 
There has been limited research conducted on whether EE has the potential to modify 
microglia and promote microglial health in AD. However, one recent study investigated 
this potential link by examining how EE might regulate microglial function in healthy 
Wt mice injected with oligomeric Aβ. Xu et al. (2016) found EE to suppress the 
elevated expression of inflammatory genes that occur in response to oligomeric Aβ, and 
a decrease in uptake of oligomeric Aβ by microglia. The decrease in Aβ phagocytosis 
was hypothesised to be due to the decrease in pro-inflammatory reaction by EE mice. 
Overall, the authors reported EE to modulate microglial morphology and density, 
leading to an increase in microglial resistance to the effects of oligomeric Aβ. 
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The study by Xu and colleagues (2016) offered significant insight into one of 
the underlying mechanisms of the protective effect of EE, and suggested EE could 
protect against AD through modulating the brain’s innate immune system. However, in 
this study, relatively young mice (approximately 3 months) were employed. It is during 
ageing that microglia are hypothesised to be less efficient at removing Aβ, and through 
the later stages of AD, perhaps become completely dysfunctional (Hickman, Allison, & 
El Khoury, 2008; Lee & Landreth, 2010). How EE might modulate the brain’s immune 
system in ageing, and through disease progression, remains unknown.  
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Table 1. EE interventions for models of amyloid pathology 
First Author 
(publication 
year) 
FAD 
mouse 
model 
n Sex Age 
entered 
into EE 
(months) 
Duration 
of EE 
Type of EE Cognitive 
function 
Aβ 
pathology 
 
Jankowsky 
(2003) 
 
APPswe, 
PSEN1dE9 
 
32 
 
F 
 
2 
 
6 
 
Constant 
with objects 
rearranged 
weekly 
 
­ 
 
 
­ 
Arendash 
(2004) 
APPSWE 13 Not 
stated 
16 3 Intermittent 
(3 x week) 
­ - 
 
Lazarov 
(2005) 
 
APPswe, 
PSEN1dE9 
 
13 
 
M 
 
1 
 
5 
 
First month 
constant (3 
hrs/day), 
then 3 x 
week 
 
Not 
assessed 
 
¯ 
Jankowsky 
(2005) 
APPswe, 
PSEN1dE9 
76 F 2 6 Constant Not 
assessed 
­ 
 
Costa 
(2007) 
 
APP+/-
PS1+/- 
 
101 
 
M + F 
 
1 
 
6 
Constant + 3 
x week 
novel 
exposure 
 
­ 
 
¯ 
 
Cracchiolo 
(2007) 
 
APPSWE, 
APPSWEPS1
M67IL 
 
38 
 
M + F 
 
1.5 
 
7 
 
Social/Physi
cal/ 
Complete + 
(novelty 
exposure 3 x 
week) 
 
 
­ 
 
 
¯ 
 
Mirochnic 
(2009) 
 
APP23 
 
38 
 
F 
 
6 & 18 
 
4 
 
Constant 
with objects 
rearranged 
 
Not 
assessed 
 
- 
 
Herring 
(2011) 
 
APP695 
 
38 
 
F 
 
1 
 
5 
 
Constant 
 
Not 
assessed 
 
¯ 
 
Valero 
(2011) 
 
APPSWE 
 
58 
 
F 
 
4 
 
1.5 
Constant 
with objects 
rearranged 
weekly 
 
­ 
 
- 
 
Cotel 
(2012) 
 
APP/PS1 
KI 
 
60 
 
F 
 
2 
 
4 
 
Constant 
with objects 
rearranged 
weekly 
 
- 
 
- 
 
Verret  
(2013) 
 
APP695 
 
112 
 
F 
 
3, 5, 10 
 
2.5 
 
Constant 
with objects 
rearranged 
 
­ 
 
Minor ¯ 
­ = EE increased relative to SH; ¯ = EE decreased relative to SH; - = no difference 
between SH and EE 
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1.5 Project Aims 
 
Searching for experimental approaches to promote brain plasticity is 
exceedingly relevant to our society in which ageing-related diseases are becoming 
increasingly prominent. Strategies aimed at boosting plasticity, or cognitive reserve, 
offer a non-invasive alternative, and avoids dangerous side effects typical of many 
pharmacological therapies. Moreover, epidemiological and experimental evidence 
demonstrates the great potential cognitive interventions may have in preventing ageing-
associated cognitive dysfunction. The encouraging data produced from animal 
enrichment studies offers hope for transferring these results to both human health and 
disease applications. 
While the animal-based literature on EE for healthy animals has a long history, 
and offers promise in staving off neurodegenerative disease, there is much to be 
elucidated. EE applied to FAD models has been focused on its effect on amyloid 
pathology, and findings have been highly variable. The literature also demonstrates a 
need for increased research on later-life interventions. While there is a wealth of 
literature supporting early-life cognitive intervention reducing dementia risk, in reality, 
people will be more likely to take up an intervention when dementia is more relevant to 
them, during ageing. In addition, as cognitive deficits emerge many years after disease 
processes start, therapies, in all likelihood, will be introduced following the onset of 
disease-induced pathology. Whether enrichment can exert similar beneficial effects in 
ageing as it does in early-life, is still a relatively unanswered question. Moreover, there 
is limited research on the efficacy of an intervention after disease processes are 
initiated. The effects of EE on Aβ pathology have been demonstrated to be contentious, 
and potential moderating factors such as how EE affects the brain’s immune cells, 
synaptic health, and stress hormones have received limited attention. 
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1.5.1 Aim 1: Investigate the effect of mid-life environmental enrichment on 
cognitive and synaptic health in healthy and Alzheimer’s disease-associated 
pathological ageing 
 
Early-life cognitive enrichment may reduce the risk of experiencing cognitive 
deterioration and dementia in later-life. However, an intervention to prevent or delay 
dementia is likely to be taken up in mid to later-life. Moreover, previous studies have 
demonstrated the effect of EE on amyloid (Aβ) pathology to be variable, with the effect 
of EE on synaptic connectivity receiving limited attention. Hence, the aim of this study 
was to investigate the effects of environmental enrichment (EE) in wildtype (Wt) mice 
and in a mouse model of Aβ neuropathology (APPSWE/PS1dE9; APP/PS1) from 6 
months of age. This transgenic mouse model recapitulates pathology that most closely 
resembles the initial stages of AD, and Aβ deposits have been observed from 4-6 
months of age in this model, with abundant plaques present by 9 months (Jankowsky et 
al. 2004; Garcia-Alloza et al. 2006; Vickers et al. 2009). After 6 months of housing in 
standard laboratory cages (minimal stimulation), APP/PS1 and healthy Wt mice were 
randomly assigned to either enriched (EE) or standard housing (SH). Following the 6-
month differential housing period, cognitive function was tested in order to determine 
whether EE initiated in mid-life, and after Aβ plaque deposition, was associated with 
heightened cognitive function as has been reported for early-life EE. Next, Aβ plaque 
burden, synaptic, BDNF protein levels were analysed, followed by analysis of synaptic 
density in the regions Fr2, CA1, and CA3. 
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1.5.2 Aim 2: Examine the effect of complex, novel environmental enrichment on 
Aβ neuropathology 
 
The literature surrounding the effect that EE has on Aβ neuropathology is variable, 
however, there is some evidence that more complex and novel enrichment may be 
required in order to buffer AD-related neuropathology. The aim of this study was to 
examine whether there may be a ‘dose’ effect of EE, with added periodic augmentation 
of stimulation (EE+) in FAD animals from mid-life (6 months of age). In order to 
examine dose-effects of EE in mid to later-life, mice were raised in SH conditions until 
6 months, and then randomly assigned to SH, EE or enhanced EE (EE+) conditions, 
where the animals remained until 12 months of age. Moreover, some evidence suggests 
that EE might be associated with lowered stress, which might explain a reduction in Aβ 
burden following EE in some studies. Following the differential housing period, stress 
hormone levels (corticosterone), Aβ plaque load and levels of Aβ42 were examined in 
neocortex and hippocampus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 45	
1.5.3 Aim 3: Explore the effect of late-life environmental enrichment on cognitive 
function and microglia 
 
Ageing-related alterations to microglia are increasingly recognised as a vital contributor 
to AD pathogenesis. EE from early life has been robustly associated with neural and 
cognitive protection, and more recently the brain’s immune system has been 
demonstrated to be vital in this link. However, there has been limited work on how EE 
potentially effects the brain’s immune cells, such as microglia, in pathological and non-
pathological ageing. The aim of this study was to assess whether EE initiated in later 
life, and at a stage of advanced Aβ pathology, would lead to positive cognitive effects 
as demonstrated in the mid-life cohort. In regions important for learning and memory 
processes, the neocortex and hippocampus, the area occupied by microglia was 
examined and compared between groups, and correlated with cognitive measures.  
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2.  Materials and Methods 
 
2.1 Mice 
 
Animals were housed in standard conditions (and environmental enrichment as 
described below), comprising ad libitum access to food and water, and housed at 20°C, 
on a 12/12-hour light/dark cycle. All experimental procedures were performed in 
accordance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes, and approved by the University of Tasmania Animal Ethics 
Committee (A13253). 
 
2.1.1 Transgenic mouse model of Alzheimer’s disease 
 
Male transgenic mice expressing chimeric mouse/human amyloid precursor 
protein (APP) and mutant human presenilin 1 (PS1) on C57BL/6 background [B6.Cg-
Tg (APPswe, PSEN1dE9) 85Dbo/J] (APP/PS1; Jankowsky et al. 2004) were used for the 
present study. This transgenic mouse model recapitulates pathology that most closely 
resembles the initial stages of AD, and Aβ deposits have been observed from 4-6 
months of age in this model, with abundant plaques present by 9 months (Jankowsky et 
al. 2004; Garcia-Alloza et al. 2006; Vickers et al. 2009). 
 
2.2 Genotyping 
 
Tail clippings were sampled from mice at weaning, and in order to extract 
genomic DNA, the tail clippings were incubated in 45µl of extraction solution 
(QUANTA Biosciences) for 30 minutes at 95°C. APP/PS1 genotypes were 
distinguished from Wt mice by standard polymerase chain reaction (PCR) using MyTaq 
Red Mix (Bioline) and primers (GeneWorks) for the PS1 transgene, and IL-2 was 
included as an internal control. Resulting PCR products were electrophoresed on a 2% 
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agarose gel (Bioline) with 0.0001% SYBR safe DNA gel stain (Invitrogen) at 120V for 
35 minutes. The subsequent bands present at 608 bp (PS1) and 324 bp (IL-2) were 
visualised using a Carestream 4000MM Pro image station. 
 
2.3 Mid-life environmental enrichment paradigm  
 
All animals lived in standard housing (SH) conditions comprising group 
housing of 4-5 mice per 30 x 30 x 14 cm cage, ad Libitum access to food and water, an 
igloo, one small wooden stick and one tissue from weaning until 6 months of age. 
APPswePSEN1dE9 (APP/PS1; n = 27) and littermate wildtype control (Wt; n = 21) mice 
were randomly assigned to SH or EE conditions at 6 months of age, for the following 6 
months. The EE housing condition consisted of a larger 60 x 30 x 14 cm cage with the 
contents of the SH cage and the addition of enrichment objects (wooden and plastic 
blocks of differing shapes and sizes, platforms, a ball, running wheel, and a mouse hut). 
Housing conditions were maintained until the 12-month end-point. 
 
2.3.1 Mid-life environmental complexity and novelty paradigm 
 
All animals lived in standard housing (SH) conditions comprising group 
housing of 4-5 mice per 30 x 30 x 14 cm cage, ad Libitum access to food and water, an 
igloo, one small wooden stick and one tissue from weaning until 6 months of age. At 6 
months, APPswePSEN1dE9 (APP/PS1; n = 40) and littermate wildtype control (Wt; n = 
31) mice were entered into the environmental enrichment plus complexity and novelty 
condition (EE+). The EE+ condition involved the mice being exposed to a larger (36 x 
49 x 22 cm) cage three times per week for a three-hour period during the dark cycle. 
The EE+ cage contained novel enrichment objects that were different to the EE cage 
(e.g. steps, ladder, tunnels, mazes, objects of differing textures, a large running wheel, 
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see-saw, platforms, chew-toys). Housing conditions were maintained until the 12-
month end-point. 
 
2.3.2 Late-life environmental enrichment paradigm 
 
All animals lived in standard housing (SH) conditions comprising group 
housing of 4-5 mice per 30 x 30 x 14 cm cage, ad Libitum access to food and water, an 
igloo, one small wooden stick and one tissue from weaning until 12 months of age. 
APPswePSEN1dE9 (APP/PS1; n = 15) and littermate wildtype control (Wt; n = 17) mice 
were randomly assigned to SH or EE conditions (as in mid-life EE paradigm) at 12 
months of age, for the following 6 months. Housing conditions were maintained until 
the 18-month end-point. 
 
2.4 Behavioural and cognitive assessment 
 
Following arrival, mice were allowed to acclimatize for 7 days prior to any 
testing. Animals were handled daily and habituated to the test room during the 
acclimatization period to minimize the effects of stress due to handling at time of 
testing. All cognitive testing procedures occurred at the same stage of the light/dark 
cycle for each test. Black curtains surrounded the test equipment whilst mice were 
tested in order to prevent the mice becoming distracted, or from using extra-maze cues. 
Testing equipment was wiped down with 70% ethanol between each trial in order to 
prevent mice using odour cues. The experimenter was blind to genotype of animals. 
The test room was kept quiet during test periods, and test room lighting was kept 
constant throughout all testing. All testing was recorded using a JVC digital camera 
mounted to the ceiling for later analysis. All behaviour testing was manually scored 
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from the recorded videos, and later validated with the automated tracking software, 
EthoVision XT. 
 
2.4.1 Y Maze spatial short-term memory 
 
Hippocampal-dependent spatial short-term recognition memory was assessed by 
the Y maze, a maze consisting of three arms placed 120° apart, with a black and white 
visual cue at the end of each arm. The two-trial Y maze task is a test based on the innate 
tendency of rodents to explore novel environments (Dellu, Contarino, Simon, Koob, & 
Gold, 2000; Wang, Ma, & van den Buuse, 2006). Mice were tested at 6 or 12-month 
baseline, after 3 months of differential housing, and at completion of the 6-month 
differential housing period. All mice underwent an initial training trial, where a 
randomly assigned arm of the Y-maze was blocked (novel arm). Mice were randomly 
designated to and placed in a start arm facing the wall of the arm, and were allowed to 
explore the two open arms for 10 minutes. Following training, mice were returned to 
their home cage for the 1 hour inter-trial interval period. The testing phase began one 
hour after the training phase. Mice were entered into the designated start arm as in 
training, and were able to freely explore all arms of maze including the previously 
blocked novel arm. Mice were allowed to explore the Y-maze for 5 minutes after 
leaving the start arm. Exclusion criteria applied were failing to leave the start arm after 
5 minutes, escaping from the Y-maze, or climbing over the arm barrier in the training 
phase. Y-maze testing was recorded for later analysis. 
 
2.4.2 Barnes maze spatial learning & long-term memory 
 
The apparatus is a white circular platform positioned 60 cm above the ground, 
that contains 20 holes evenly spaced around the perimeter of the platform. A hidden 
escape box was positioned underneath one of the holes. Four visual cues were placed on 
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curtains surrounding the maze at a distance of approximately 50 cm from the perimeter 
of the platform (Nithianantharajah & Hannan, 2006). Mice were initially habituated to 
the maze by being placed on the maze and allowed to freely explore for two 5-minute 
adaptation trials. Twenty-four hours after adaptation, a seven-day training period begin. 
Training was performed under bright light (approximately 300W) in order to motivate 
mice to find the hidden escape box. As this is a test of spatial memory, each mouse had 
the same designated escape position on the maze, however, each mouse was randomly 
assigned one of four different escape positions to overcome bias. Mice underwent two 
training trials per day for seven days in which they were initially placed under an 
opaque start box in the centre of the maze. After 30s, the start box was lifted and the 
mouse was able to freely explore the platform. The trial ended when the mouse had 
climbed into the hidden escape, or after 5 minutes had elapsed. After each trial, the 
maze and escape box were wiped down with 70% ethanol and the maze was rotated to 
prevent olfactory cues. Fourteen days after the 7-day training period had elapsed, long-
term memory was assessed using the same protocol as in training. 
 
2.5 Tissue collection 
 
Following the final day of behavioural testing all mice were weighed to ensure 
no significant group differences that could confound experiments, and were terminally 
anaesthetized first with gas anaesthesia (isoflurane) followed by sodium pentobarbitone 
(100 mg/kg delivered intraperitoneally). For histology, animals were perfused 
transcardially with 4% paraformaldehyde (PFA) in 0.1M phosphate buffered saline 
(PBS, pH 7.4). Postmortem brains were transferred to 18% then 30% sucrose solutions 
overnight. Brains for histology were serially sectioned on a cryostat (Leica CM 1850) 
in 40µm coronal sections. Sections used for analysis were from bregma 2.0 - -3.0 mm 
according to the stereotaxic mouse brain atlas (Paxinos & Franklin, 2008). For Western 
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blotting and Enzyme-linked immunosorbent assay (ELISA) procedures, animals were 
transcardially perfused with PBS (0.1M). Postmortem brains were removed and the 
cortex and hippocampus were dissected and immediately frozen in liquid nitrogen. 
Cortex and hippocampal samples were stored at -80°C for later analysis. 
 
2.6 Immunohistochemistry and histological stains 
 
2.6.1 Thioflavin-S staining for Aβ plaques 
 
Thioflavin-S (Sigma-Aldrich) staining was performed in order to visualise 
fibrillar and dense-core Aβ plaques (Dickson & Vickers, 2001). Ten serial sections 
evenly spaced throughout the rostrocaudal axis of the brain from bregma 2.0 - -3.0 mm 
according to the stereotaxic mouse brain atlas (Paxinos & Franklin, 2008) were 
incubated in the solution (0.125% Thioflavin-S diluted in 60% absolute ethanol with 
40% 0.01M PBS) for 3 minutes at room temperature, and washed for 2 x 1 minute in 
50% absolute ethanol and 50% 0.01M PBS solution, followed by 3 x 10 minute washes 
in 0.01M PBS. Sections were mounted using Dako fluorescent mounting medium.  
 
2.6.2 MOAB-2 immunohistochemistry for Aβ plaques 
 
For the quantitation of Aβ deposits, antigen retrieval by formic acid treatment 
was performed in order to enhance immunoreactivity for the visualization of Aβ 
deposits (Kai et al., 2012). Ten sections evenly spaced across the rostrocaudal extent of 
the brain (bregma 2.0 - -3.0 mm) were incubated in 88% formic acid (Sigma-Aldrich) at 
room temperature for 8 minutes, followed by 6 x 10 minute PBS washes. Free-floating 
sections were washed for 3 x 10 minutes in 0.25% Triton-X-100 and incubated with 
serum-free protein block (Dako) for 15 minutes at room temperature. The sections were 
immunolabelled with the MOAB-2 antibody (1:2000; Novus Biologicals, Table 2.1) 
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which specifically labels mouse and human un-aggregated Aβ, following the protocol 
outlined in Collins, King, Woodhouse, Kirkcaldie and Vickers (2015). MOAB-2 
labelling was visualized by incubation in Alexa-fluorophore conjugated secondary 
antibody (1:1000; Molecular Probes, goat anti-mouse IgG2b-546, Table 2.2) and cover-
slipped using Dako fluorescent mounting medium.  
 
2.6.3 Immunohistochemistry for synaptophysin puncta 
 
To determine region-specific alterations in synaptic density, synaptophysin 
immunoreactive puncta were quantitated histologically in specific areas of the brain 
including the dorsomedial region of the murine prefrontal cortex, frontal area 2 (Fr2) 
and the hippocampal subregions CA1 and CA3 (Figure 2.1). Five images across three 
sections within Fr2 (bregma 1.98 – 0.38 mm) and five images across CA1 and CA3 
(bregma –1.28 - -2.12 mm) were immunostained with primary anti-synaptophysin 
antibody (1:200; Millipore, Table 2.1) using Alexa-fluorophore secondary antibody, 
goat-anti-rabbit IgG 594 (Molecular Probes, Table 2.1). To highlight architecture, 
sections were also incubated with the nuclear stain DAPI (5 µg/mL; Invitrogen) for 5 
minutes at room temperature. Sections were mounted using fluorescent mounting 
medium (Dako).  
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Figure 2.1. Regions selected for synapse analysis. A Right hemisphere of coronal 
mouse brain section displaying Fr2. B Image of hippocampus showing CA1 and CA3 
subregions. 
 
 
2.6.4 Immunohistochemistry for microglia 
 
Three sections at approximately bregma 1.045, -1.855, and -2.88 mm were 
incubated in formic acid as described for MOAB-2, and immunolabelled with the Iba1 
antibody (1:1000; Wako, Table 2.1) which recognises the ionized calcium binding 
adaptor molecule 1, labelling microglia. The Iba1 antibody and the labelling was 
visualised by incubation with Alexa-fluorophore conjugated secondary antibody 
(1:1000; Molecular probes, goat anti-mouse IgG2b -546, Table 2.2). The sections were 
mounted using Dako fluorescent mounting medium.  
 
2.7 Image acquisition 
 
In order to determine Aβ plaque load in the cortex and hippocampus, images 
were obtained with a Leica DM fluorescence microscope on a 10x objective and NIS 
Elements imaging software. Ten sections evenly spaced from the rostral to caudal 
extent of the cerebral cortex from bregma position 2.0 to -3.0 mm were imaged for 
MOAB-2 and Thioflavin-S Aβ plaque load. The left side of the cortex was imaged from 
the midline to the rhinal fissure (rf; Figure 2.2). Images of the whole hippocampus were 
taken between bregma position -1.22 and -2.46 mm of 3-5 sections per animal. Aβ 
plaque load (defined as percentage area occupied by MOAB-2 immunoreactivity or 
Thioflavin-S fibrillar staining) was determined by random forest segmentation (O’Mara 
et al. manuscript in preparation). 
Imaging of Synaptophysin and Iba1 labelling was performed on a Perkin-Elmer 
Ultraview VOX confocal imaging system with Volocity 6.3 imaging software. For 
synaptophysin imaging, all images were acquired with the same laser power and 
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exposure settings, using a 60x objective. Five images/section were taken within Fr2, 
CA1, and CA3 subregions of 3 sections/animal. For APP/PS1 animals, Aβ plaque free 
regions were included in the analysis. An imageJ watershed algorithm with Gaussian 
blurring (σ = 1) was applied and synaptophysin positive puncta were automatically 
segmented by random forest classification (O’Mara et al. manuscript in preparation) 
and an ImageJ watershed algorithm was applied to the segmented images. Particles 
ranging from 0.15 to 2.0 µm2 were quantified (Stanislaw Mitew, Kirkcaldie, Dickson, 
& Vickers, 2013). Synaptic density was calculated as the number of Synaptophysin 
immunolabelled puncta per field, corrected for cell body area. Three sections at bregma 
positions 1.045, -1.855, and -2.88 mm stained with Iba1 were imaged using a 20x 
objective, and all images were acquired with the same laser power and exposure 
settings. Images of neocortex from the corpus collosum to the rhinal fissure and whole 
hippocampus were acquired.  
 
Figure 2.2. One hemisphere of coronal mouse brain section stained with the MOAB-2 
antibody, outlining the regions of analysis for plaque load. 
 
 
 
midline	
rf	
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2.8 Random forest classification for the analysis of histology 
 
Images of brain sections stained with Thioflavin-S, MOAB-2, Synaptophysin, 
and Iba1, were processed to 8-bit greyscale images, and segmented with a custom 
plugin for ImageJ. Segmentation included an automated random forest classifier 
(Sommer et al., 2011; Figure 2.3) which utilizes supervised machine learning. 
Supervised machine learning is an alternative method of analysing histological data to 
thresholding the images, and is more effective at discriminating image artefacts, is 
robust against variability in staining intensity, and is more objective relative to 
thresholding techniques (Holmes, Kapelner, & Lee, 2009; Sommer, Straehle, Kothe, & 
Hamprecht, 2011). Here, the classifier was trained with a random selection of example 
images for each marker, which were annotated in order to detect immunostaining from 
background pixels. A learning algorithm was developed taking into account a 
combination of image metrics that provide the most reliable discrimination of signal 
pixels from background (e.g. colour, edges, texture). The custom random forest 
classifier used in these studies, was developed by O’Mara and Kirkcaldie (Manuscript 
in preparation). It should be noted that images of cortex and hippocampus sections 
display a tiling-edge effect (e.g. Figure 5.2), and so values may not be absolute. 
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Figure 2.3. APP/PS1 mouse neocortex stained with Thioflavin-S and resulting image 
following random forest segmentation shows plaques for analysis. 
 
 
2.8 Western blotting and ELISA 
 
Neocortex and hippocampus were homogenized in RIPA buffer (Sigma) 
containing a protease (Roche diagnostics) and phosphatase inhibitor cocktail (AG 
Scientific). The samples were centrifuged at 13000 RPM for 15 minutes, rotated for a 
further 30 minutes, and centrifuged again at 4°C for 15 minutes at 13000 RPM. The 
resulting supernatant was removed and stored at -80°C for protein analysis. The protein 
concentrations of samples were determined using the Bradford assay.  
 
2.8.1 Western blotting 
 
For western blotting, samples were prepared as a total volume of 10µl 
containing 10µg of protein per lane. The samples were separated (3 repeats/sample) on 
a 12% NuPage Novex Bis-Tris gel (Invitrogen) by electrophoresis at 200V for 20 
minutes at room temperature. Following, proteins were transferred to an activated 
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PVDF membrane at 20V for 60 minutes. Membranes were blocked for 2 hours in 5% 
commercial skim milk powder. Membranes were incubated in primary antibodies 
overnight at 4°C in combinations of rabbit anti-synaptophysin (1:2000, Millipore); 
mouse anti-VGlut1 (1:1000, Millipore); mouse anti-PSD-95 (1:1000, Abcam) mouse 
anti-GAD65; mouse anti-GAD67 (1:1000, Millipore), rabbit anti-Gephyrin (1:1000, 
Abcam) and anti-β-actin (1:5000, Sigma-Aldrich) (Table 2.1). Membranes were washed 
in Tris-buffered saline with 0.1% Tween-20 (Sigma) and incubated in species-
appropriate secondary antibodies (1:7000, Dako, Table 2.2). Bands were visualised by 
staining with a chemiluminescent substrate kit (Millipore). 
 
2.8.2 Aβ42 ELISA 
 
Neocortex and hippocampus were homogenized in RIPA buffer (Sigma) 
containing a protease (Roche diagnostics) and phosphatase inhibitor cocktail (AG 
Scientific). The samples were centrifuged at 13000 RPM for 15 minutes, rotated for a 
further 30 minutes, and centrifuged again at 4°C for 15 minutes at 13000 RPM. The 
resulting supernatant was removed and stored at -80°C for protein analysis. The protein 
concentrations of samples were determined using the Bradford assay. For the 
quantitation of human Aβ42, a sandwich antibody ELISA was performed according to 
the manufacturer’s instructions (KHB3441, Invitrogen). APP/PS1 mice (n = 5 per 
group) were terminally anaesthetized first with gas anaesthesia (isoflurane) followed by 
sodium pentobarbitone (100 mg/kg delivered intraperitoneally) and perfused 
transcardially with PBS (0.1M). Postmortem brains were removed and the cortex and 
hippocampus were dissected and immediately frozen in liquid nitrogen. Cortex and 
hippocampal samples were stored at -80°C for later analysis. Soluble human Aβ42 levels 
were normalized to total protein levels and expressed as picogram of Aβ42 content per 
milligram of total protein (pg/mg). Optical densities were read at 450 nm on a 
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microplate reader (SpectraMax, Molecular Devices), and concentrations of Aβ42 were 
determined by comparison to the standard curve using a 4-parameter algorithm. 
 
2.8.3 Corticosterone ELISA  
 
In order to determine if there were differences in levels of stress between the 
housing conditions and genotypes, blood was collected at time of perfusion by cardiac 
puncture, performed at the start of the dark period (3 p.m.). Blood samples were 
centrifuged for 5 minutes at 13 000 RPM and the resulting sera was collected. The sera 
samples were diluted at 1:100 in the buffer provided, and levels of serum corticosterone 
were measured by a competitive commercial ELISA kit (ab108821; Abcam) according 
to manufacturer instructions. Optical densities were read at 450 nm on a microplate 
reader (SpectraMax, Molecular Devices), and concentrations of corticosterone were 
determined by comparison to the standard curve using a 4-parameter algorithm. 
 
2.8.4 BDNF ELISA 
 
Each sample was prepared in duplicate and diluted in coating buffer (1:100; 
60% NaHCO3, 30% Na2CO3 in distilled water), and 50 µl of diluted sample was added 
per well to a 96-well flat-bottomed plate (Costar 5395, Sigma-Aldrich) and incubated at 
4°C overnight. Following overnight incubation, the plate was washed five times with 
washing buffer (0.05% tween-20 in 0.01M PBS). Following, 100 µl of blocking buffer 
(5% fetal calf serum in 0.01M PBS) was added to each well and incubated at 37°C for 
30 minutes. Following five washes, 50 µl of diluted primary BDNF antibody (1:500; 
Santa Cruz, Table 2.1) was added to each sample well, and incubated at room 
temperature for 1 hour. Five washes were undertaken and the secondary HRP antibody 
was added (1:2000; anti-Rabbit, Dako, Table 2.2) and incubated at room temperature 
for 45 minutes. Following washing, 100 µl of freshly prepared Tetramethylbenzidine 
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(TMB; Sigma-Aldrich) substrate was applied to each well for 10 minutes, and 0.1M 
Sulphuric acid was added to stop the colour reaction. Optical densities were read at 450 
nm on a microplate reader (SpectraMax, Molecular Devices), and concentrations of 
BDNF were determined by comparison to the standard curve using a 4-parameter 
algorithm. Values were averaged between the duplicate samples, and expressed as a 
percentage relative to Wt controls. 
 
2.9 Statistical analyses 
 
Analyses were performed using IBM SPSS (Version 20;). Statistical analyses 
were performed using independent t-tests, two-way analysis of variance (ANOVA), and 
repeated measures ANOVA. A statistically significant two-way ANOVA was followed 
up by separate independent t-tests, where the variables considered were genotype (Wt 
or Tg) and housing condition (SH or EE). When the variables considered were SH, EE, 
and EE+, a statistically significant two-way ANOVA was followed up with post hoc 
tests with Bonferroni correction applied for multiple comparisons. Means were reported 
as ± the standard error of the mean (SEM). The magnitude of differences between the 
means were reported as Cohen’s d. Values of p < .05 for differences between group 
means were classified as statistically significant. 
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Table 2.1. List of primary antibodies 
Antibody name Host 
organism 
(Clone) 
Isotype Immunizing agent  Source 
(catalogue 
number) 
 Dilution 
MOAB-2 Mouse monoclonal 
IgG2b 
 
 
C-terminal for Aβ40 and 
Aβ42 (Youmans et al., 
2012)  
 
 
 
Novus 
Biologicals 
(NBP2-
13075) 
 1:2000 (IHC) 
Synaptophysin Rabbit polyclonal IgG 
 Synthetic peptide of 
human synaptophysin 
(313 amino acids) (Rehm, 
Wiedenmann, & Betz, 
1986)  
 
Millipore 
(AB9272)  
 
 
1:200 (IHC) 
 
1:2000 (WB) 
 
VGlut1 Mouse monoclonal IgG1 
Recombinant protein from 
rat VGlut1 (560 amino 
acids) (Fazzari et al., 
2014) 
 Millipore 
(MAB5502) 
 
 1:1000 (WB)  
 
PSD-95 
 
Mouse 
monoclonal 
(clone 6G6-
1C9) 
IgG2a 
Recombinant protein from 
rat PSD-95 (Li et al., 
2010) 
 
Abcam 
(Ab2723)  1:1000 (WB) 
 
Gephyrin 
 
 
Rabbit 
polyclonal 
 
IgG 
Synthetic peptide of 
human Gephyrin (amino 
acids 396-445) (Harvey et 
al., 2004)  
 
 
Abcam 
(Ab83401) 
 
 
 
1:1000 (WB) 
GAD65 
 
Mouse 
monoclonal 
(clone GAD-
6) 
IgG2a 
Purified GAD65 from rat 
(585 amino acids) (Besser 
et al., 2015) 
 
 
Millipore 
(MAB351)  1:1000 (WB) 
 
GAD67 
 
Mouse 
monoclonal 
(clone 
1G10.2) 
IgG2a 
Recombinant GAD67 
protein (594 amino acids) 
(Fong, Stornetta, Foley, & 
Potts, 2005) 
 
 
Millipore 
(MAB5406) 
 1:1000 (WB) 
 
β-actin 
 
Mouse 
monoclonal 
(clone AC-
74) 
IgG2a 
Modified β-cytoplasmic 
actin N-terminal peptide 
(Arellano, Guadiana, 
Breunig, Rakic, & 
Sarkisian, 2012) 
 
 
 
Sigma-
Aldrich 
(A5316) 
 1:5000 (WB) 
BDNF 
 
Rabbit 
polyclonal 
IgG 
Epitope mapping, internal 
region of Human BDNF 
(amino acids 128-147) 
(Flores-Otero & Davis, 
2011) 
  
 
Santa Cruz 
(SC-546)  
1:500 
(ELISA) 
Iba1 Rabbit  
Synthetic peptide 
corresponding to C-
terminus of Iba1from 
rabbit (Ito et al., 1998) 
 
Wako (019-
19741)  1:1000 (IHC) 
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Table 2.2. List of secondary antibodies 
 
Emission (nm) Species/Reactivity Dilution Supplier (catalogue 
number) 
488 Goat/Mouse IgG1 1:1000 Molecular probes (A-
11001) 
546 Goat/Mouse IgG2b 1:1000 Molecular probes (A-
21143) 
488 Goat/Rabbit IgG 1:1000 Molecular probes (A-
11008 
546 Goat/Rabbit 1:1000 Molecular probes (A-
11035) 
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Chapter 3 
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3. Mid-life environmental enrichment increases synaptic density in 
CA1 in a mouse model of Aβ-associated pathology and positively 
influences synaptic and cognitive health in healthy ageing 
 
3.1 Introduction 
 
Interventions to reduce the burden of dementia-causing diseases are urgently 
needed given global ageing and the current lack of effective therapeutic approaches. 
Epidemiological investigations suggest an active cognitive lifestyle may offer 
protection against the clinical expression of dementia (Valenzuela, Brayne, Sachdev, 
Wilcock, & Matthews, 2011), potentially by building resilience to the underlying 
pathology and compressing cognitive morbidity to later stages of disease. In order to 
mimic the benefits of enhanced cognitive stimulation, an EE paradigm in experimental 
animals is often employed. An EE paradigm typically involves the manipulation of an 
animals’ environment in order to facilitate sensory, cognitive, and motor stimulation 
(van Praag et al., 2000; Nithianantharajah & Hannan, 2006).  
There is a wealth of evidence supporting EE-induced cognitive and neural 
benefit in a range of animal models of neurodegenerative disease (Nithianantharajah & 
Hannan 2006). However, the reported effects on a hallmark pathological feature of AD, 
Aβ plaques, in familial Alzheimer’s disease (FAD) animal models have been variable. 
Following an EE intervention, reduction (Lazarov et al., 2005; Costa et al., 2007; 
Herring et al., 2011), no change (Arendash et al., 2004; Wolf et al., 2006; Cotel, 
Jawhar, Christensen, Bayer, & Wirths, 2012), or an exacerbation of Aβ pathological 
burden (Jankowsky et al., 2003; 2005) has been reported in transgenic mice expressing 
human FAD-related gene mutations. Notably, many of these EE studies have involved 
such stimulation (EE) from weaning or in early-life. Despite the variation between 
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studies regarding Aβ pathological alterations following EE, there is a consensus of 
marked protection of cognitive function following this intervention. 
 In this regard, the underlying mechanism allowing for cognitive protection is 
elusive. EE in other models may influence synaptic connectivity in order to provide 
cognitive benefit (Nithianantharajah & Hannan, 2006). Moreover, BDNF, a protein 
expressed widely throughout the CNS, vital for the maintenance, survival, and growth 
of neurons (Mattson et al., 2004) has been implicated in both AD and EE. As BDNF 
mediates synaptic plasticity and cognitive function (e.g. Murer et al., 2001; Lu, 2003), it 
is thought that BDNF may be critically involved in the pathophysiology underlying  
cognitive decline in AD. Moreover, reduced levels of BDNF are found in the 
hippocampus and frontal and parietal cortices of the AD brain (Ferrer et al., 1999; Hock 
et al., 2000). BDNF promotes synapse formation (Park & Poo, 2013) and thus could be 
a potential target for diseases of synaptic plasticity failure, such as in AD. To date, 
BDNF has not been able to be delivered across the blood-brain barrier (Lu et al., 2013). 
However, some evidence suggests EE may be able to increase endogenous levels of 
BDNF in healthy animals (Ickes et al., 2000; Ramírez-Rodríguez et al., 2014; Novkovic 
et al., 2015).  
With respect to human interventions of relevance to dementia and EE, the 
benefit of early-life cognitive stimulation, in the form of education, on later-life 
cognitive function has been well reported (e.g. Anstey & Christensen 2000; Lenehan, 
Summers, Saunders, Summers & Vickers, 2014). However, research on the potential 
protective effects of later-life cognitive engagement and enrichment is limited. The 
Tasmanian Healthy Brain Project (THBP; Summers et al., 2013) has produced the first 
research on the potential benefit of formal late-life education on cognitive reserve 
(Lenehan et al., 2015). However, investigation of later-life EE in animal models of 
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neuropathology has been limited. Moreover, whether cognitive intervention introduced 
at the inception of AD-neuropathology produces benefit is unknown. This concept is 
difficult to test in human cases considering dementia is typically detected many years 
after the AD-related neuropathology forms (Braak & Del Tredici, 2011). 
In the current study, we investigated the effects of an EE intervention in a FAD 
transgenic model (APPswePS1dE9 line; APP/PS1) from 6 months of age to model an 
intervention targeted to mid-life. The APP/PS1 mouse model begins to show Aβ plaque 
pathology by 6 months of age (Garcia-Alloza et al., 2006) and most closely resembles 
earlier stages of human AD in terms of synapse loss and neuritic pathology (Mitew, 
Kirkcaldie, Dickson & Vickers, 2013a, b). It was hypothesized that EE would produce 
positive cognitive effects associated with less vulnerability of, or increased levels of 
synaptic markers, rather than a reduction in Aβ neuropathology. 
We examined region-specific alterations in synapses following EE. The 
dorsomedial region of the murine prefrontal cortex, frontal area 2 (Fr2), involved in 
complex cognitive functions (Uylings, Groenewegen, & Kolb, 2003) was selected. In 
addition, we examined the hippocampal subregions CA1 and CA3 due to their role in 
spatial learning and memory (Anderson et al., 2006; Kesner, 2007). These regions are 
not only potential targets of EE evidenced by increases in working memory and spatial 
learning and memory in rodent models exposed to EE, but are also highly susceptible to 
AD (Vickers et al., 2000; Patrylo & Williamson, 2007; Morrison & Baxter, 2014).   
 
 
 
 
 
 
 
 
	 67	
3.2 Materials and Methods 
 
 
3.2.1 Animals and EE protocol 
 
Male transgenic mice expressing chimeric mouse/human amyloid precursor 
protein (APP) and mutant human presenilin 1 (PS1) on C57BL/6 background [B6.Cg-
Tg (APPswe, PSEN1dE9) 85Dbo/J] (APP/PS1; Jankowsky et al., 2004) were used for 
the present study (described in Chapter 2). All animals lived in standard housing (SH) 
conditions comprising group housing of 4-5 mice per 30 x 30 x 14 cm cage, ad Libitum 
access to food and water, an igloo, one small wooden stick and one tissue. 
APPswePSEN1dE9 (APP/PS1; n = 27) and littermate wildtype control (Wt; n = 21) mice 
were randomly assigned to SH or EE conditions at 6 months of age, for the following 6 
months (EE paradigm outlined in Chapter 2). 
 
3.2.2 Cognitive and behavioural assessment general protocol 
 
Mice were handled daily and habituated to the test room for 7 days prior to 
testing to minimize the effects of stress due to handling at time of testing. All cognitive 
testing procedures occurred at the same stage of the light cycle. Black curtains 
surrounded the test equipment during testing, in order to prevent the mice becoming 
distracted, or from using extra-maze cues. Testing equipment was cleaned with 70% 
ethanol between trials in order to prevent odour cues. The experimenter was blind to the 
genotype of animals. Noise was minimized and lighting was kept constant throughout 
all testing. Exclusion criteria for behavioural testing were defined prior to testing, and 
adhered to. All testing was recorded for later analysis using a JVC digital camera 
mounted to the ceiling. 
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3.2.2.1 Y Maze spatial short-term memory 
 
All mice underwent a 10-minute acquisition trial, where a randomly assigned 
arm of the Y maze was blocked (novel arm). The testing phase began after a 1-hour 
inter-trial interval, where all three arms of the maze were open for exploration for 5 
minutes. Y maze testing was recorded for later analysis, where the percentage of time 
spent in the novel arm was calculated as a percentage of the total time in all three arms. 
Testing was performed immediately before being assigned to differential housing, in 
order to establish baseline performance, after 3 months of differential housing and 
finally after 6 months at end-point. 
 
3.2.2.2 Barnes maze spatial learning & long-term memory 
 
Testing on the Barnes maze was performed following 6 months of differential 
housing. Mice were initially habituated to the maze by being able to freely explore the 
maze for two 5-minute adaptation trials. Twenty-four hours after adaptation, a seven-
day training period began of two trials per day. The trial ended when the mouse had 
climbed into the hidden escape, or after 5 minutes had elapsed. Fourteen days after the 
7-day training period had elapsed, long-term memory was assessed with four trials. The 
latency to reach the escape box in each trial was recorded for analysis. 
 
3.2.3 Tissue collection 
 
Following the final day of behavioural testing, mice were terminally 
anaesthetized first with gas anaesthesia (isoflurane) followed by sodium pentobarbitone 
(100 mg/kg delivered intraperitoneally). For histology (Wt n = 11; APP/PS1 n = 17), 
animals were perfused transcardially with 4% paraformaldehyde (PFA) in 0.1M 
phosphate buffered saline (PBS pH 7.4). Postmortem brains were transferred to 18% 
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then 30% sucrose solutions overnight. Brains for histology were serially sectioned on a 
cryostat (Leica CM 1850) in 40µm coronal sections. Sections used for analysis were 
from bregma 2.0 - -3.0 mm according to the stereotaxic mouse brain atlas (Paxinos & 
Franklin, 2008). For Western blotting procedures, animals (Wt n = 10; APP/PS1 n = 
10) were transcardially perfused with PBS (0.1M). Postmortem brains were removed 
and the neocortex and hippocampus were dissected and immediately frozen in liquid 
nitrogen, and samples were stored at -80°C for later analysis. 
 
3.2.4 Antibody characterization 
 
 All antibodies used in the present study are commercially available and have 
been previously characterized (see Table 2.1 for references). Optimal antibody 
concentrations were determined for each antibody. Control experiments were 
performed by omitting primary antibodies, which eliminated all immunoreactivity. Aβ 
deposits were detected by immunohistochemistry using a mouse monoclonal antibody 
(MOAB-2) with an epitope at residues 1-4 (manufacturer information). The MOAB-2 
antibody is raised against human Aβ, and recognises human unagreggated, oligomeric, 
and fibrillar forms of Aβ42, but not APP (Youmans et al., 2012). Previous work from 
our lab has confirmed the specificity and labelling pattern of the MOAB-2 antibody, 
which co-labels with the commonly used anti-Aβ antibody, 6E10 (Collins et al., 2015). 
Synaptic puncta were visualized by immunolabelling with the pan-presynaptic marker, 
synaptophysin. The synaptophysin antibody is a polyclonal antibody raised in rabbit, 
the immunogen is a full-length (313 amino acids) synthetic peptide from human 
synaptophysin, and labels a single band at approximately 38 kDa on western blots 
(manufacturer’s information). 
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The following antibodies were used for Western blot in the present study, and 
recognise the expected band on a Western blot of mouse brain tissue. The molecular 
sizes of the immunoreactive bands are: mouse anti-VGlut1, 60 kDa; mouse anti-PSD-
95, 95 kDa; Rabbit anti-Gephyrin, 80 kDa; mouse anti-GAD65, 65 kDa; mouse 
GAD67, 67 kDa; mouse anti-β-actin (internal control), 42 kDa. The antibody rabbit 
anti-BDNF was used for ELISA, the antibody detects precursor and mature BDNF, and 
labels bands at 32 kDa (precursor) and 14 kDa (mature) (manufacturer information). 
Table 2.1 shows full antibody information. 
 
3.2.5 Quantitation of Aβ plaques 
 
For the quantitation of Aβ deposits, antigen retrieval by formic acid treatment 
was performed in order to enhance immunoreactivity for the visualization of Aβ 
deposits (Kai et al., 2012). Ten sections evenly spaced across the rostrocaudal extent of 
the brain (bregma 2.0 - -3.0 mm) were incubated in formic acid (Sigma-Aldrich) at 
room temperature for 8 minutes, followed by 6 x 10 minute PBS washes. Free-floating 
sections were washed for 3 x 10 minutes in 0.25% Triton-X-100 and incubated with 
serum-free protein block (Dako) for 15 minutes at room temperature. The sections were 
immunolabelled with the MOAB-2 antibody (1:2000; Novus Biologicals, Table 2.1) 
which specifically labels mouse and human un-aggregated Aβ, following the protocol 
outlined in Collins, King, Woodhouse, Kirkcaldie and Vickers (2015). MOAB-2 
labelling was visualized by incubation in Alexa-fluorophore conjugated secondary 
antibody (1:1000; Molecular Probes, goat anti-mouse IgG2b-546, Table 2.2) and cover-
slipped using Dako fluorescent mounting medium.  
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3.2.6  Quantitation of synaptophysin immunoreactive puncta 
 
To determine region-specific alterations in synaptic density, synaptophysin 
immunoreactive puncta were quantitated histologically in the dorsomedial region of the 
murine prefrontal cortex, frontal area 2 (Fr2; Van De Werd, Rajkowska, Evers, & 
Uylings, 2010) and the hippocampal subregions CA1 and CA3 (Paxinos & Franklin, 
2008).  Three sections containing Fr2 (bregma 1.98 – 0.38 mm) and three sections that 
contained CA1 and CA3 (bregma –1.28 - -2.12 mm) were immunostained with primary 
anti-synaptophysin antibody (1:200; Millipore, Table 2.1) according to standard 
procedures (Collins et al., 2015) using Alexa-fluorophore secondary antibody, goat-
anti-rabbit IgG 594 (Molecular Probes, Table 2.2). To highlight architecture, sections 
were also incubated with the nuclear stain DAPI (5 µg/mL; Invitrogen) for 5 minutes at 
room temperature. Sections were mounted using fluorescent mounting medium (Dako).  
 
3.2.7 Image acquisition 
 
In order to determine Aβ plaque load in the neocortex and hippocampus, images 
were obtained with a Leica DM fluorescence microscope on a 10x objective and NIS 
Elements imaging software. Ten sections evenly spaced from the rostral to caudal 
extent of the neocortex from bregma position 2.0 to -3.0 mm were imaged for MOAB-2 
Aβ plaque load. The left side of the neocortex was imaged from the midline to the 
rhinal fissure. Images of the whole hippocampus were taken between bregma position -
1.22 and -2.46 mm of 3-5 sections per animal. Aβ plaque load (defined as percentage 
area occupied by MOAB-2 immunoreactivity) was determined by applying a custom 
plugin for ImageJ to the plaque images, which automatically segmented images as 
plaques or background pixels by random forest classification, as described by Sommer 
et al. (2011). The classifier was trained with a random selection of example plaque 
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images from the data set, which were annotated in order to distinguish plaques from 
background pixels.  
Imaging of synaptophysin labelling was performed on a Perkin-Elmer Ultraview 
VOX confocal imaging system with Volocity 6.3 imaging software. All images were 
acquired with the same laser power and exposure settings, using a 60x objective. Five 
images (image window size = 118.15 x 118.15µm)/section were taken within Fr2, CA1, 
and CA3 subregions across three sections/animal. For APP/PS1 animals, Aβ plaque free 
regions were included in the analysis. These images then underwent image 
segmentation and random forest classification in order to distinguish synaptic puncta 
from background pixels using the custom imageJ plugin as described for plaque load 
analysis. An imageJ watershed algorithm with Gaussian blurring (σ = 1) was applied to 
the segmented images. Particles ranging from 0.15 to 2.0µm2 were quantified (Mitew et 
al., 2013a). Synaptic density was calculated as the number of synaptophysin 
immunolabelled puncta per field (118.15 x 118.15µm), corrected for cell body area. 
 
3.2.8 Western blotting 
 
The right side of the neocortex and hippocampus were homogenized in RIPA 
buffer (Sigma) containing a protease (Roche diagnostics) and phosphatase inhibitor 
cocktail (AG Scientific). The samples were centrifuged at 13000 RPM for 15 minutes, 
rotated for a further 30 minutes, and centrifuged again at 4°C for 15 minutes at 13000 
RPM. The resulting supernatant was removed and stored at -80°C for protein analysis. 
The protein concentrations of samples were determined using the Bradford assay. 
Samples were prepared as a total volume of 10µl containing 10µg of protein per lane. 
The samples were separated (3 repeats/sample) on a 12% NuPage Novex Bis-Tris gel 
(Invitrogen) by electrophoresis at 200V for 20 minutes at room temperature. Following, 
proteins were transferred to an activated PVDF membrane at 20V for 60 minutes. 
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Membranes were blocked for 2 hours in 5% commercial skim milk powder. Membranes 
were incubated in primary antibodies overnight at 4°C in combinations of rabbit anti-
synaptophysin (1:2000, Millipore); mouse anti-VGlut1 (1:1000, Millipore); mouse anti-
PSD-95 (1:1000, Abcam) mouse anti-GAD65; mouse anti-GAD67 (1:1000, Millipore), 
rabbit anti-Gephyrin (1:1000, Abcam) and anti-β-actin (1:5000, Sigma-Aldrich) (Table 
2.1). Membranes were washed in Tris-buffered saline with 0.1% Tween-20 (Sigma) and 
incubated in species-appropriate secondary antibodies (1:7000, Dako, Table 2.2). Bands 
were visualised by staining with a chemiluminescent substrate kit (Millipore). 
 
3.2.9 BDNF Enzyme-linked immunosorbent assay (ELISA) 
 
Neocortex and hippocampal samples were prepared as described for Western 
blotting. Briefly, each sample was prepared in duplicate and diluted in coating buffer 
(1:100; 60% NaHCO3, 30% Na2CO3 in distilled water), and 50 µl of diluted sample was 
added per well to a 96-well flat-bottomed plate (Costar 5395, Sigma-Aldrich) and 
incubated at 4°C overnight. Following overnight incubation, the plate was washed five 
times with washing buffer (0.05% tween-20 in 0.01M PBS). Following, 100 µl of 
blocking buffer (5% fetal calf serum in 0.01M PBS) was added to each well and 
incubated at 37°C for 30 minutes. Following five washes, 50µl of diluted primary 
BDNF antibody (1:500; Santa Cruz, Table 2.1) was added to each sample well, and 
incubated at room temperature for 1 hour. Five washes were undertaken and the 
secondary HRP antibody was added (1:2000; anti-Rabbit, Dako, Table 2.2) and 
incubated at room temperature for 45 minutes. Following washing, 100µl of freshly 
prepared Tetramethylbenzidine (TMB; Sigma-Aldrich) substrate was applied to each 
well for 10 minutes, and 0.1M Sulphuric acid was added to stop the colour reaction. 
Optical densities were read at 450 nm on a microplate reader (SpectraMax, Molecular 
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Devices), and concentrations of BDNF were determined by comparison to the standard 
curve using a 4-parameter algorithm. Values were averaged between the duplicate 
samples, and expressed as a percentage relative to Wt controls. 
 
3.2. Statistical analysis 
 
Analyses were performed using IBM SPSS (Version 20). Statistical analyses 
were performed using independent t-tests, two-way ANOVA, and repeated measures 
ANOVA. A statistically significant two-way ANOVA was followed up by separate 
independent t-tests. Variables considered were genotype (Wt or Tg) and housing 
condition (SH or EE). Values of p < .05 for differences between group means were 
classified as statistically significant. 
 
3.3 Results 
 
3.3.1 Body weight 
 
 No significant differences in body weight were detected between groups, F (1, 
42) = 1.60, p = .21. 
 
3.3.2 Pre-intervention and follow-up short-term memory  
 
In order to assess cognitive changes following exposure to EE, we first 
established baseline short-term memory (STM) function using the Y maze at six- 
months of age. An independent t-test revealed APP/PS1 animals spent significantly less 
time in the novel arm of the maze compared to the Wts (t (46) = 3.15, p = .003), an 
indication of a STM deficit. Following 3 months of differential housing, a two-way 
ANOVA demonstrated no significant genotype x housing effect on Y maze 
performance, F (1, 42) = 2.26, p = .14. However, when Wt and APP/PS1 groups were 
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analysed separately, an independent t-test demonstrated for APP/PS1 mice, those in EE 
spent significantly more time in the novel arm of the maze than those in SH (t (18) = 
3.75, p = 0.002) (Figure 3.1A) (Table 3.1). 
 
3.3.3 Post-intervention short-term memory  
 
Following 6 months of differential housing, at 12 months of age, no significant 
genotype x housing effect on Y maze performance was detected by two-way ANOVA 
(F (1, 43) = 0.20, p = 0.66). Moreover, a two-way repeated measures ANOVA of the three 
testing time-points revealed that Y maze performance over time was not significantly 
affected by housing x genotype (F (2, 82) = 2.07, p = 0.13) (Figure 3.1A) (Table 3.1). 
 
 
Table 3.1. Mean percentage time in novel arm of the Y maze 
 SH 
Wt 
 
M 
 
 
 
(SD) 
 
 
 
n 
EE 
Wt 
 
M 
 
 
 
(SD) 
 
 
 
n 
SH 
Tg 
 
M 
 
 
 
(SD) 
 
 
 
n 
EE 
Tg 
 
M 
 
 
 
(SD) 
 
 
 
n 
Baseline 
6 
months 
 
51.63 12.00 13 53.33 9.89 14 41.39 15.79 11 41.15 13.56 10 
9 
months 
 
36.72 14.80 12 42.89 14.84 14 27.72 11.24 10 45.41 9.04 9 
12 
months 
41.56 15.59 12 50.83 14.70 14 51.51 18.15 10 53.09 20.69 9 
 
 
3.3.4 Post-intervention learning & long-term memory  
 
A Greenhouse-Geisser corrected repeated measures ANOVA of learning on the 
Barnes maze demonstrated no significant main effect of genotype x housing on learning 
(F (9.19, 280.18) = 0.56, p = 0.87) (Figure 3.1B) (Table 3.2). In addition, a two-way 
ANOVA demonstrated no significant genotype x housing effect on long-term memory 
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performance (F (1, 46) = 2.78, p = 0.10) (Figure 3.1C). A separate independent t-test of 
Wt animals, demonstrated that those in EE when compared to those in SH, 
demonstrated a significantly reduced latency to reach the escape on the LTM trial (t (25) 
= 2.07, p = 0.049). However, analysis of the Tg animals revealed EE did not have a 
significant effect on LTM (t (10.94) = 0.39, p = 0.71). 
 
 
Table 3.2. Latency (s) to reach escape on the Barnes Maze learning trials 
Trial SH Wt 
M (SD) 
EE Wt 
M (SD) 
SH Tg 
M (SD) 
EE Tg 
M (SD) 
1 179.42 (81.67) 121.75 (86.16) 133.85 (78.96) 147.55 (78.21) 
2 125.96 (65.14) 97.54 (62.53) 171.85 (99.52) 127.60 (99.85) 
3 114.67 (86.33) 53.96 (44.96) 104.40 (46.80) 92.35 (80.99) 
4 109.88 (70.04) 104.38 (90.87) 121.15 (75.10) 116.65 (92.72) 
5 106.00 (73.37) 74.96 (83.07) 109.10 (78.01) 120.25 (87.36) 
6 118.71 (87.78) 60.46 (82.12) 87.55 (43.27) 84.40 (49.37) 
7 116.38 (92.00) 67.58 (48.01) 94.80 (73.18) 110.65 (58.37) 
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Figure 3.1. Y maze and Barnes maze performance. A Mean percentage of time spent in 
the novel arm of the Y maze (± SEM) at baseline, and after 3 and 6 months of 
differential housing. Baseline testing at 6 months of age demonstrated APP/PS1 mice 
spent significantly less time in the novel arm of the Y maze, t (46) = 3.15, p = 0.003. 
After 3 months of housing, no genotype x housing effect on Y maze performance was 
detected, F (1, 42) = 2.26, p = 0.14. Following 6 months of differential housing, no 
significant genotype x housing effect on Y maze performance was detected, F (1, 43) = 
0.20, p = 0.66. B Mean latency (± SEM) to reach the escape on the Barnes maze over 7 
days of learning trials at 12 months of age. No significant main effect of genotype x 
housing on learning was detected, F (9.19, 280.18) = 0.56, p = 0.87. C Long-term memory 
performance on the Barnes maze expressed as the mean latency (± SEM) to reach the 
escape over four trials. The EE Wt animals on average had significantly reduced 
latency to reach the escape, t (25) = 2.07, p = 0.049. * p <.05, **p <.01, ***p <.001. 
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3.3.5 Aβ plaque load 
 
In order to determine whether EE introduced after the onset of Aβ 
neuropathology alters β-Amyloid load, we analysed MOAB-2 immunolabelling, an 
antibody that recognises human and mouse unaggregated, oligomeric, and fibrillar 
forms of Aβ42 and unaggregated Aβ40 (Youmans et al., 2012). An independent t-test 
of Aβ plaque load in the neocortex measured by MOAB-2 immunolabelling, did not 
differ significantly according to housing condition at 12 months (t (15) = 0.65, p = 0.53) 
(Table 3.3). Additionally, no significant difference in hippocampal MOAB-2 
immunolabelling was detected by independent t-test (t (15) = 0.18, p = 0.86) (Table 3.3) 
(Figure 3.2). 
 
 
Table 3.3. MOAB-2 load (% area) of Neocortex and Hippocampus 
 SH 
n = 9 
M (SEM) 
EE 
n = 8 
M (SEM) 
Neocortex 
 
29.44 (2.75) 25.76 (5.15) 
Hippocampus 25.42 (2.35) 24.74 (2.92) 
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Figure 3.2. Representative APP/PS1 mouse brain sections stained with the MOAB-2 
antibody. A APP/PS1 mouse brain coronal section with MOAB-2 positive plaques from 
SH. B APP/PS1 mouse brain coronal section with MOAB-2 positive plaques from EE. 
 
 
3.3.6 Western blots of synaptic markers 
 
In order to assess the effect of EE on synapses in APP/PS1 and Wt mice, we 
quantified levels of synaptic proteins in the neocortex and hippocampus by Western 
blotting, and analysed group differences by two-way ANOVA. A significant housing x 
genotype effect was detected for labelling with the pan-presynaptic protein, 
synaptophysin, in the neocortex (F (1, 16) = 8.12, p = 0.01) (Figure 3.3B), and in the 
hippocampus (F (1, 16) = 9.43, p = 0.008) (Figure 3.4B). Subsequent independent t-tests 
showed that Wt animals in EE, as compared to Wts in SH, had relatively increased 
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cortical (t (8) = 3.22, p = 0.01) and hippocampal (t (8) = 3.51, p = 0.008) synaptophysin 
levels. 
To further examine whether these effects could be attributed to excitatory or 
inhibitory synaptic changes, antibody markers VGlut-1, PSD-95, gephyrin, and 
GAD65/67 were examined. No housing x genotype effect was detected in the excitatory 
synaptic marker VGlut-1 in the cortex (F (1, 16) = 0.15, p = 0.70) (Figure 3.3C), or in the 
hippocampus (F (1, 16) = 0.007, p = 0.94) (Figure 3.4C). No significant housing x 
genotype effect was detected for levels of the excitatory post-synaptic marker, PSD-95 
in the cortex (F (1, 16) = 0.003, p = 0.95) (Figure 3.3D). However, there was differential 
expression in the hippocampus (F (1, 16) = 8.99, p = 0.009). When genotypes were 
analysed separately, Wt EE animals had higher hippocampal levels of PSD-95 
compared to the Wts in SH (t (8) = 2.84, p = 0.02) (Figure 3.4D). Gephyrin labelling was 
not significantly altered by the effect of housing x genotype in neocortex (F (1, 16) = 
1.42, p = 0.25) (Figure 3.3E) or in hippocampus (F (1, 16) = 1.13, p = 0.31) (Figure 3.4E). 
However, analysing the Wt and APP/PS1 animals separately demonstrated that 
enriched Wt animals had significantly lower hippocampal gephyrin labelling as 
compared to those in SH (t (8) = 3.06, p = 0.02). The inhibitory synaptic marker 
GAD65/57 was significantly affected by housing x genotype (F (1, 16) = 5.54, p = 0.03). 
Analysing genotypes separately demonstrated increased GAD65/57 protein levels in 
neocortex of Wt EE animals (t (7.45) = 2.64, p = 0.03) (Figure 3.3F). However, this effect 
was not detected in the hippocampus (F (1, 16) = 0.02, p = 0.90) (Figure 3.4F). 
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Figure 3.3 Mean synaptic protein levels expressed as a percentage relative to Wt 
control (± SEM) from neocortex samples. A Representative Western blot bands per 
group for each synaptic marker. B Synaptophysin: EE Wt mice had higher relative 
levels of cortical synaptophysin, t (8) = 3.22, p= 0.01. C VGlut-1: No significant 
differences across housing x genotype were detected, F (1, 16) = 0.15, p = 0.70. D PSD-
95: No significant differences across housing x genotype were detected, F (1, 16) = 0.003, 
p = .95. E Gephyrin: No significant differences across housing x genotype were 
detected, F (1, 16) = 1.42, p = 0.25. F GAD65/67: Wt EE mice showed significantly 
increased levels of GAD65/67 compared to those in SH, t (7.45) = 2.64, p = 0.03. * p 
<.05, **p <.01, ***p <.001. 
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Figure 3.4. Mean synaptic protein levels expressed as a percentage relative to Wt 
control (± SEM) from hippocampus samples. A Representative Western blot bands per 
group for each synaptic marker. B Synaptophysin: EE Wt mice had significantly higher 
hippocampal synaptophysin compared to SH Wt mice, t (8) = 3.51, p = 0.008. C VGlut-
1: There was no significant housing x genotype effect on VGlut-1 expression in the 
hippocampus, F (1, 16) = 0.007, p = 0.94. D PSD-95: Wt EE mice had significantly 
higher levels of PSD-95 compared to SH Wt t (8) = 2.84, p = 0.02. E Gephyrin: EE Wt 
mice had significantly lower levels of hippocampal gephyrin as compared to SH Wt, t 
(8) = 3.06, p = 0.02. F GAD65/67: No significant differences were detected across 
housing x genotype in the hippocampus, F (1, 16) = 0.02, p = 0.90. * p <.05, **p <.01, 
***p <.001. 
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3.3.7 Synaptophysin immunolabelling in Fr2, CA1, and CA3 
 
Quantification of immunolabelled synaptophysin puncta of the dorsomedial 
region of the prefrontal cortex, Fr2, showed no significant housing x genotype 
alterations in synaptophysin (F (1, 24) = 0.07, p = 0.79) (Figure 3.5). Housing x genotype 
did not significantly influence CA1 synaptophysin immunolabelling (F (1, 24) = 0.94, p = 
0.34) (Figure 3.6). However, an independent t-test demonstrated that, for the APP/PS1 
animals, EE produced a significant increase in synaptophysin density in CA1 (t (16) = 
2.54, p = 0.02). However, no significant effect of housing x genotype on levels of 
synaptophysin density was found within CA3, (F (1, 24) = 2.79, p = 0.12) (Figure 3.7). 
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Figure 3.5. Synapse density in Fr2 of neocortex.  Representative 60x (118.15 x 118.15 
µm) synaptophysin staining in Fr2 per group, Scale bar = 20µm. Mean synaptophysin 
density (± SEM) of Fr2 showed no significant housing x genotype effect, F (1, 24) = 0.07, 
p = 0.79.  
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Figure 3.6.  Synapse density in hippocampal subregion CA1. Representative 60x 
(118.15 x 118.15 µm) synaptophysin staining in CA1, Scale bar = 20µm. Mean 
synaptophysin density of CA1 (± SEM), the APP/PS1 mice from EE had significantly 
higher synaptophysin density in CA1, t (16) = 2.54, p = 0.02, relative to the other groups. 
* p <.05, **p <.01, ***p <.001. 
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Figure 3.7. Synapse density in hippocampal subregion CA3.  Representative 60x 
(118.15 x 118.15 µm) synaptophysin staining in CA3, Scale bar = 20µm. Mean 
synaptophysin density CA3 (± SEM) showed no significant housing x genotype effect, 
F (1, 24) = 2.79, p = 0.12.  
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3.3.8 BDNF protein levels in neocortex and hippocampus 
 
A two-way ANOVA demonstrated relative levels of BDNF were not altered in 
neocortex across genotype or housing condition (F (2, 23) =0.88, p = 0.43) (Figure 3.8A). 
A two-way ANOVA also revealed no genotype x housing effect on hippocampal BDNF 
(F (2, 23) = 1.04, p = 0.37). However, when genotypes were considered separately, an 
independent t-test demonstrated a significant increase in hippocampal BDNF in 
APP/PS1 mice housed in EE compared to mice housed in SH (t (8) = 3.39, p = 0.009) 
(Figure 3.8B). 
 
 
 
 
 
Figure 3.8. BDNF protein levels relative to Wt control (% expression ± SEM). A 
BDNF expression in neocortex is not altered by genotype or housing, F (2, 23) =0.88, p = 
0.43. B BDNF expression in hippocampus was elevated in APP/PS1 mice housed in EE 
relative to the SH condition, t (8) = 3.39, p = 0.009. * p <.05, **p <.01, ***p <.001. 
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3.4 Discussion 
 
The global scale related to the predicted rise in the prevalence of AD (Prince et 
al., 2015) has led to increased research strategies aimed at delaying the onset of 
dementia. A substantial literature supports the proposal that a stimulating lifestyle 
beginning in early-life has beneficial later-life effects on cognitive ageing, potentially 
by buffering against pathological damage, compressing cognitive morbidity to later 
years. However, the effect of a cognitive intervention targeted at mid-life is not well 
understood. Moreover, whether cognitive stimulation can enhance the compensatory 
capacity of synaptic connectivity for existing pathology is unknown. Here, the effect of 
mid-life EE in experimental models of normal ageing and Aβ neuropathology was 
investigated.  
The results of the present study demonstrate that EE initiated after Aβ plaque 
deposition has begun does not modify the course of subsequent amyloid pathology. 
However, EE differentially produced changes in cognitive function and synaptic 
markers. The data demonstrated the relationship between EE and synaptic health and 
cognitive function was not straightforward. Rather, it was found that EE in healthy 
ageing mice led to increased inhibitory synaptic markers in the cortex and elevated 
excitatory receptor markers in the hippocampus, along with superior long-term memory 
function. However, relative to Wt mice, and perhaps due to increased mutant APP/PS1 
expression or AD-related pathology, the APP/PS1 mice did not show as extensive 
changes in synaptic protein levels or in cognitive function afforded by EE. However, 
EE produced an increase in synaptic density in CA1 in this model of Aβ 
neuropathology, and ameliorated some aspects of cognitive dysfunction associated with 
ageing and the APP/PS1 genotype. 
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With regards to the current study, there have been conflicting reports regarding 
the age of cognitive impairment onset in the APP/PS1 mouse model of AD. In the 
current report, a STM deficit was observed in APP/PS1 mice at 6 months of age. Other 
reports support the finding of the current study, where a STM deficit was observed at 6 
months of age (Zhang et al., 2006; Aso et al., 2012; Izco et al., 2014). One explanation 
for an early STM deficit might be the dramatic increase in Aβ deposition at this time-
point (Izco et al., 2014), resulting in neural disruption at the microcellular level.  
Y maze testing after 3 months of EE demonstrated improved STM performance 
by the APP/PS1 animals. This finding suggested EE can abate the initial STM deficit in 
this mouse line. However, this beneficial effect did not persist at 12 months of age, with 
STM performance being similar across all animal groups. Moreover, Barnes maze 
testing at 12 months demonstrated superior LTM following 6 months of EE in Wt mice. 
This finding suggests that LTM function in ageing can benefit from EE, however, the 
presence of Aβ pathology may diminish this benefit. Although the present study had a 
relatively large sample size for FAD transgenic studies (Table 1), this enrichment 
paradigm may have induced more subtle cognitive changes that we did not have power 
to detect in the current study. One other interpretation for the lack of cognitive benefit 
to the APP/PS1 mice following 6 months of stimulation, is the increasing burden of Aβ 
pathology by 12 months attenuated the effect of EE. The results must also be 
interpreted with the features of this mouse model in mind, this APP/PS1 model being 
most closely aligned to the long, preclinical stage of human AD (Mitew et al. 2013a, b). 
Consistent with several studies, the current data showed that Aβ plaque burden 
was not modified by EE (Arendash et al., 2004; Jankowsky et al., 2003; 2005; Wolf et 
al., 2006; Cotel et al., 2012), indicating that this intervention does not modify disease 
process progression. However, other studies have reported EE to directly attenuate Aβ 
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neuropathology (Lazarov et al., 2005; Cracchiolo et al., 2007). Potential discrepancies 
may be due to the time-point at which enrichment was initiated. The majority of studies 
have investigated EE introduced at weaning, or in early-life, and before the deposition 
of Aβ plaque pathology. Arendash et al. (2004) in an APPSW model of AD, also 
demonstrated that later-life EE did not reduce Aβ load. Relatedly, Verret et al. (2013) 
reported decreased Aβ load following early-life EE, whereas EE introduced later in life 
did not lead to reductions in Aβ burden. These findings together suggest that EE does 
not have a modifying effect on plaque formation once Aβ deposition has commenced. 
EE as a potential non-pharmacological intervention may have effects on the 
structural plasticity of synapses. In this respect, there have been a number of studies 
that have demonstrated synaptic changes as a result of EE (Nithianantharajah & 
Hannan, 2006). An increase in the expression of synaptophysin has been demonstrated 
following EE in healthy Wt animals in the neocortex and hippocampus 
(Nithianantharajah et al., 2004; Lambert, Fernandez, & Frick, 2005; Birch, Mcgarry, & 
Kelly, 2013). However, these results were obtained in young animals, and the 
relationship between enrichment, synaptophysin, and cognitive function in ageing is 
less clear. The present study demonstrated EE in ageing promotes synaptophysin 
expression in cortical and hippocampal regions, and is associated with relatively 
superior LTM performance. It has been suggested that, as synaptophysin is a 
component of neurotransmitter-containing presynaptic vesicle membranes, the increase 
in synaptophysin is potentially reflective of an increase in neurotransmission, that may 
in turn lead to improved spatial LTM (Frick & Fernandez, 2003). 
The Wt mice that experienced EE exhibited relatively increased levels of 
inhibitory synaptic proteins in the cortex, and both increased excitatory and decreased 
inhibitory synaptic protein levels in the hippocampus. Cortical inhibition is vital in 
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coordinating network activity and maintaining cortical function (Isaacson & Scanziani, 
2011). In contrast, the APP/PS1 mice from both housing conditions exhibited relatively 
high levels of both inhibitory and excitatory synaptic protein, suggesting an imbalance 
of the interplay between excitatory and inhibitory activity. A high level of Aβ is 
associated with aberrant excitatory network activity and compensatory inhibitory 
responses (Palop & Mucke, 2010). Aβ may affect excitatory and inhibitory synapses 
differently, thereby creating complex imbalances in neuronal circuit activity.  
While both AD and EE induce widespread alterations to the brain, in AD some 
brain regions are more affected than others. One notable finding of the present study 
was the increase in the number of synaptophysin labelled puncta within the CA1 region 
of EE APP/PS1 mice. Consistent with these findings, CA1 activity has been found to 
increase when rodents are exposed to novel environments (Nitz & McNaughton, 2004; 
Cracchiolo et al., 2007; Csicsvari, O’Neill, Allen, & Senior, 2007; Karlsson & Frank, 
2008). Similarly, an increase in CA1 synaptic density in healthy rodents following EE 
has been previously reported (Moser, Trommald, & Andersen, 1994; Moser, Trommald, 
Egeland & Andersen, 1997; Rampon et al. 2000; Malik & Chattarji, 2012).  
Although the finding of increased CA1 synaptic connectivity following EE has 
been previously reported, the novelty here is that we found an increase in CA1 synaptic 
density in a model of Alzheimer’s pathology, suggesting that this region retains 
capacity for experience-dependent plasticity in response to EE, despite the presence of 
accumulating Aβ neuropathology. An increase in the number of synapses in plaque-free 
brain regions in this mouse model at 12 months of age has been previously reported 
(West, Bach, Søderman & Jensen, 2009; Mitew et al. 2013a). While the CA1 region is 
not plaque free, Aβ plaques occupy only a negligible fraction of CA1 in FAD mouse 
models (Merino-Serrais, Knafo, Alonso-Nanclares, Fernaud-Espinosa, & Defelipe, 
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2011). Early-stage AD is characterised by attenuated synaptic plasticity, triggering a 
compensation response by the formation of new synapses in an attempt to preserve 
synaptic connectivity (King & Arendash, 2002; Selkoe, 2002; Boncristiano et al., 2005; 
Jansen et al., 2012). Here, the heightened number of synaptic contacts in the APP/PS1 
mice may be a compensatory response to synaptic dysfunction (West et al., 2009). As 
EE targets CA1, it follows that the combination of this compensation response paired 
with stimulation of CA1 by EE would lead to an increase in synaptic density within this 
region.  
The finding of an increase in hippocampal BDNF in APP/PS1 mice exposed to 
EE might suggest BDNF to be a mediator of the beneficial effects of EE. Stimulation of 
CA1 has been observed to increase hippocampal BDNF levels (Kealy & Commins, 
2010). Moreover, hippocampal BDNF plays a critical role in learning and memory 
processes (Cowansage, LeDoux, & Monfils, 2010), potentially allowing for the 
APP/PS1 mice with unaltered Aβ plaque burden to demonstrate superior STM 
following 3 months of EE. 
The findings presented here indicate EE initiated in mid-life promotes an array 
of beneficial effects in healthy ageing in terms of enhancing synaptic and cognitive 
health. Such findings are remarkable considering the lack of stimulation in early-life, 
suggesting later-life interventions may be able to overcome some of the negative effects 
of minimal stimulation earlier in life. However, when ageing also involves Aβ 
neuropathology, EE does not influence global positive effects as seen in healthy ageing. 
Although, EE after Aβ deposition has commenced, was associated with a more specific 
alteration, an increase in the number of synaptic contacts in the AD-vulnerable CA1 
subregion, and an increase in hippocampal BDNF protein levels. These data 
demonstrate that plasticity processes are afforded by EE in specific brain regions 
	 95	
despite the presence of accumulating Aβ neuropathology. Hence, non-pharmacological 
interventions such as EE introduced during the preclinical stage of disease may promote 
compensatory mechanisms that enhance synaptic connectivity. Moreover, the findings 
presented in this Chapter demonstrates that an intervention targeted to mid-life based on 
EE has the potential to promote synaptic and cognitive health in healthy ageing. 
This Chapter was designed to examine the effect of EE in mid-life, and 
following the deposition of Aβ in the FAD model, on subsequent Aβ load, and on 
cognitive and synaptic health. The findings presented in this Chapter offer no 
straightforward relationship between mid-life EE and these factors. Rather, there was a 
spectrum of differential effects produced from EE between healthy Wt and FAD model 
mice. Overall, mid-life EE in healthy Wt mice, was associated with a balance to 
inhibitory and excitatory synaptic connectivity, and positive effects on long-term 
memory. FAD mice exhibited more specific, and subtle effects, showing a shorter-term 
cognitive benefit in spatial short-term memory, and an increase in hippocampal BDNF 
and CA1 synaptic density. The finding of an increase in hippocampal BDNF and 
synaptic connectivity, is notable given the presence of accumulating Aβ 
neuropathology. The findings of this Chapter, of no alterations to subsequent amyloid 
pathology when EE is introduced after Aβ deposition are consistent with that of Verret 
and colleagues (2013).  However, EE following Aβ-pathological onset has also been 
shown to reduce Aβ load (Herring et al., 2011). One limitation of research into EE, is 
that various EE paradigms are employed (Xu, Yu, Tan, & Tan, 2015), which potentially 
leads to differences in the amount of stimulation from the environment received. Here, 
the animals lived in a constant enriched environment. However, it is possible that a 
more intensive and novel form of stimulation may be required to buffer AD-related 
neuropathology. 
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4. Environmental novelty exacerbates stress hormones and Aβ 
pathology in an Alzheimer’s model 
 
 
                                                                                                                                                                   
4.1 Introduction 
 
Research has consistently demonstrated that the environment influences the 
brain both structurally and functionally over the lifetime (Sale, Berardi, & Maffei, 
2009). In this respect, among modifiable factors that are associated with a reduced risk 
of developing dementia, is living a cognitively engaged life. Indeed, those who engage 
in high levels of cognitive activity have approximately half the risk of developing 
dementia than those who engage in low levels (Valenzuela & Sachdev, 2006). As 
discussed in Chapter 1 and 3, stimulation from the environment in animal models has a 
variable effect on Aβ pathological burden in transgenic mice expressing human FAD-
related gene mutations, with reported decreased (Lazarov et al., 2005; Costa et al., 
2007; Herring et al., 2011), no change (Arendash et al., 2004; Wolf et al., 2006; Cotel et 
al., 2012), or increased (Jankowsky et al., 2003; 2005) Aβ load. As demonstrated in the 
previous Chapter, EE from mid-life was not associated with alterations to subsequent 
Aβ plaque pathology in a FAD mouse model.  
As discussed in Chapter 1, it is possible that more complex, and novel 
stimulation may be required to buffer AD-related neuropathology (Valenzuela & 
Sachdev, 2006). Therefore, in this Chapter, a potential ‘dose’ effect of EE was 
investigated, with added periodic augmentation of stimulation (EE+). In order to 
examine dose-effects of EE in mid to later-life, mice were raised in SH conditions until 
6 months as in Chapter 3, and then randomly assigned to SH, EE, or an enhanced 
environmental enrichment (EE+) condition, where the animals remained until 12 
months of age.  
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4.2 Methods 
 
4.2.1 Animals and EE protocol 
 
 As for Chapter 3, male mice expressing chimeric mouse/human amyloid 
precursor protein (APP) and mutant human presenilin 1(PS1) on C57BL/6 background 
(APP/PS1; Jankowsky et al., 2004) and littermate wildtype (Wt) control mice were 
used. Animals were housed in standard housing (SH) conditions (see Chapter 2 for 
description) until 6 months of age. At 6 months, mice were randomly assigned to SH, 
EE, or EE+ conditions for the following 6 months. The mid-life EE protocol as detailed 
in Chapter 2 was followed for SH and EE housing paradigms. The EE+ condition 
involved the mice being exposed to a larger (36 x 49 x 22 cm) cage three times per 
week that contained novel enrichment objects (changed weekly; Chapter 2). Housing 
conditions were maintained until the 12-month end-point.  
 
4.2.2 Tissue collection 
 
Mice were terminally anaesthetized first with gas anaesthesia (isoflurane) 
followed by sodium pentobarbitone (100 mg/kg delivered intraperitoneally). For 
histological analysis, animals were perfused transcardially with 4% paraformaldehyde 
(PFA) in 0.1M phosphate buffered saline (PBS pH 7.4). Post-mortem brains were 
transferred to 18% then 30% sucrose solutions overnight. Brains were cut on a cryostat 
(Leica CM 1850) in 40µm coronal sections. APP/PS1 mice used for the quantification 
of human soluble Aβ42, were terminally anaesthetized as above, and perfused 
transcardially with PBS (0.1M). Post-mortem brains were removed and the cortex and 
hippocampus were dissected and immediately frozen in liquid nitrogen. Cortex and 
hippocampal samples were stored at -80°C for later analysis. 
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4.2.3 Aβ fibrillar plaque deposition 
 
Thioflavin-S (Sigma-Aldrich) staining was performed in order to visualise 
fibrillar and dense-core Aβ plaques(Dickson & Vickers, 2001). Ten serial sections 
evenly spaced throughout the rostrocaudal axis of the brain from bregma 2.0 - -3.0 mm 
according to the stereotaxic mouse brain atlas (Paxinos & Franklin, 2008) were 
incubated in the solution (0.125% Thioflavin-S diluted in 60% absolute ethanol with 
40% 0.01M PBS) for 3 minutes at room temperature, and washed for 2 x 1 minute in 
50% absolute ethanol and 50% 0.01M PBS solution, followed by 3 x 10 minute washes 
in 0.01M PBS. Sections were mounted using Dako fluorescent mounting medium.  
 
4.2.4 Image acquisition 
 
In order to determine Aβ plaque load in the cortex and hippocampus, images 
were taken on a Leica DM fluorescence microscope on a 10x objective with NIS 
Elements imaging software. The left side of the cortex was imaged from the midline to 
the rhinal fissure from bregma 2.0 - -3.0 mm of 10 sections per animal. Images of the 
whole hippocampus were taken between bregma position -1.22 and -2.46 mm of 3-5 
sections per animal. Aβ plaque load (percentage area Thioflavin-S positive) was 
calculated by random forest segmentation. Whereby, a custom plugin for ImageJ was 
applied to the images, which automatically segmented images as plaques or background 
pixels by random forest classification (Sommer et al., 2011; Chapter 2). 
 
4.2.5 Aβ42 ELISA 
 
For the quantitation of human Aβ42, a sandwich antibody ELISA was performed 
according to the manufacturer’s instructions (KHB3441, Invitrogen). Duplicate cortex 
and hippocampus samples from APP/PS1 mice (n = 5/group) were diluted in the buffer 
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provided (1:50). Soluble human Aβ42 levels were normalized to total protein levels and 
expressed as picogram of Aβ42 content per milligram of total protein (pg/mg). Optical 
densities were read at 450 nm on a microplate reader (SpectraMax, Molecular Devices), 
and concentrations of Aβ42 were determined by comparison to the standard curve using 
a 4-parameter algorithm. 
 
4.2.6 Corticosterone ELISA  
 
In order to determine if there were differences in levels of stress between the 
housing conditions and genotypes, blood was collected at time of perfusion by cardiac 
puncture, performed at the start of the dark period (3 p.m.). Serum samples were diluted 
at 1:100 in the buffer provided, and levels of serum corticosterone were measured by a 
commercial ELISA kit (ab108821; Abcam) according to manufacturer instructions. 
Optical densities were read at 450 nm on a microplate reader (SpectraMax, Molecular 
Devices), and concentrations of corticosterone were determined by comparison to the 
standard curve using a 4-parameter algorithm. 
 
 
4.2.7 Statistical analysis 
 
Statistical analyses were performed using independent t-test and two-way 
ANOVA using IBM SPSS (Version 20). A statistically significant two-way ANOVA 
was followed up by post hoc tests. Variables considered were genotype (Wt or Tg) and 
housing condition (SH, EE, or EE+). Values of p < .05 for differences between group 
means were classified as statistically significant. The magnitude of differences between 
the means were reported as Cohen’s d. 
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4.3 Results 
 
 
4.3.1 Body weight 
 
 No group differences were detected in body weight, F (2, 66) = 1.14, p = .33. 
 
4.3.2 Mid-life EE+ was associated with increased fibrillar Aβ pathology in the 
hippocampus 
 
Following the 6-month intervention, when mice were 12 months of age, it was 
hypothesised that exposure to the EE+ intervention would potentially be associated with 
a reduction in Aβ plaque burden. Fibrillar Aβ plaque load was analysed in the neocortex 
and hippocampus of APP/PS1 mice, and no significant alterations to Aβ plaque load in 
the neocortex were detected as a function of housing condition (Figure 4.1A). In 
contrast, there was a large (d = 1.08) and significant increase in hippocampal Aβ plaque 
load in APP/PS1 mice exposed to the EE+ condition (Figure 4.1B).   
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Figure 4.1. Fibrillar Aβ plaque load in neocortex and hippocampus in APP/PS1 mice 
exposed to differential housing. A Thioflavin-S staining of fibrillar and dense core Aβ 
plaques demonstrated no significant difference in plaque load in neocortex between the 
housing groups, F (2, 19) = 0.78, p = .47. B A significant effect of housing was detected 
on plaque load in the hippocampus, F (2, 19) = 4.80, p = .02. Bonferroni adjusted post 
hoc tests revealed APP/PS1 mice housed in EE+ had higher hippocampal Aβ plaque 
burden when compared to those in SH (p = .02). * p<.05, **p<.01, ***p<.001. 
 
 
 
4.3.3 Mid-life EE+ was associated with increased Aβ42 in neocortex 
 
Next, levels of soluble Aβ42 in the neocortex and hippocampus were examined, 
and an overall significant effect of housing condition on Aβ42 was found. APP/PS1 mice 
housed in EE+ showed a large (d = 1.89) and significant increase in Aβ42 in neocortex, 
compared to mice from SH or EE (Figure 4.2A). However, in contrast to the finding of 
an increase in Aβ plaque deposition in the hippocampus, this effect was not observed 
for Aβ42 levels in the hippocampus (Figure 4.2B). The data suggest that EE+ is 
associated with increases in Aβ production in the neocortex, and increased deposition of 
Aβ in the hippocampus. 
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Figure 4.2. Aβ42 levels in neocortex and hippocampus in APP/PS1 mice across 
differential housing conditions. A Overall, there was a significant effect of housing 
condition on cortical Aβ42 levels, F (2, 12) = 10.41, p = .002. Follow-up post-hoc tests 
were performed with Bonferroni correction applied. The EE+ group had significantly 
higher cortical Aβ42 compared with both SH (p = .003) and EE (p = .012). B No 
significant differences were detected in hippocampal Aβ42 levels between housing 
conditions, F (2, 12) = 0.04, p = .96. * p <.05, **p <.01, ***p <.001. 
 
 
4.3.4 APP/PS1 mice demonstrated elevated levels of corticosterone 
 
While the assumption had been that placing animals in an enhanced EE 
condition may have augmented cognitive and physical stimulation, it was also possible 
that this exposure had broader physiological effects that may have led to increased Aβ 
pathology, and that the FAD background also contributed to an unexpected reaction to 
the EE+ condition. Previous clinical studies have reported that people living with AD 
generally have higher blood-levels of the stress hormone, cortisol, when compared to 
healthy people (Rasmuson et al., 2001; Csernansky et al., 2006). However, whether the 
disease process itself alters normal stress physiology, or whether stress increases 
vulnerability to developing AD, is unknown. It is widely accepted that stress induces 
activation of the hypothalamic-pituitary-adrenocortical (HPA) axis, which leads to a 
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subsequent release of cortisol in humans, or corticosterone in rodents, from the adrenal 
cortex (Nelson, 1972; Silverman & Sternberg, 2012).  
Several studies, using experimental paradigms designed to induce stress, have 
demonstrated an accelerated onset, or faster rate of progression of AD, in FAD mouse 
models (Dong et al., 2004; Jeong et al., 2006; Carroll et al., 2011; Rothman et al., 2012; 
Baglietto-Vargas et al., 2015). Such evidence led to the hypothesis that the novelty and 
complexity conferred by the EE+ condition, elevated stress levels, which may in turn 
have increased Aβ pathological burden in APP/PS1 mice in EE+ housing. We first 
compared levels of the stress hormone, corticosterone, between healthy control Wt and 
APP/PS1 mice from the SH condition, in order to determine whether the presence of the 
APP/PS1 transgene was associated with elevated corticosterone. Corticosterone levels 
in blood serum were significantly increased in 12-month old APP/PS1 mice compared 
to healthy Wt mice, which represented a large effect (d = 1.09) (Figure 4.3). This 
finding supports the hypothesis of HPA axis dysfunction in AD. 
 
4.3.5 Mid-life EE+ was associated with elevated corticosterone levels in APP/PS1 mice 
 
Following the finding of elevated levels of corticosterone in APP/PS1 mice 
compared to Wt mice from SH, EE and EE+ conditions were included into the analysis. 
First, an overall significant interaction effect of genotype x housing on corticosterone 
levels was detected. Due to the APP/PS1 mice demonstrating increased corticosterone 
levels, genotypes were analysed separately in order to investigate housing effects. In Wt 
mice, there was no significant housing condition effect on corticosterone levels. 
However, there was a significant and large effect of housing condition for APP/PS1 
mice. While the APP/PS1 mice from SH exhibited increased corticosterone levels 
relative to Wts, APP/PS1 mice from EE+ showed further elevated corticosterone levels, 
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being significantly higher compared to APP/PS1 mice from both the SH and EE 
conditions (d = 1.05) (Figure 4.3). 
 
 
 
 
 
Figure 4.3. Differential corticosterone levels according to genotype and housing 
condition. APP/PS1 mice in SH had significantly higher levels of corticosterone in 
blood serum compared to healthy Wt control mice at 12 months, t (24) = 2.34, p = .03. 
There was a significant interaction effect of genotype x housing on levels of 
corticosterone, F (2, 66) = 3.76, p = .03. In Wt mice, there was no significant effect of 
housing on corticosterone, F (2, 28) = 0.31, p = .74. Housing condition produced a 
significant effect on corticosterone levels in APP/PS1 mice, F (2, 38) = 4.8, p = .01. 
Bonferroni adjusted post hoc tests revealed EE+ mice had significantly higher 
corticosterone levels compared to SH (p = .02). Moreover, EE+ mice had higher 
corticosterone levels than mice housed in EE (p = .049), however, this was no longer 
significant when Bonferroni correction was applied (p = .057). * p <.05, **p <.01, ***p 
<.001. 
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4.4 Discussion 
 
This Chapter was designed to examine whether more complex, and novel 
stimulation, would confer a reduction to Aβ pathology relative to a more stable form of 
stimulation, as was employed in Chapter 3. In this study, the APP/PS1 mouse model 
showed elevated stress-hormone levels compared to Wt animals of a similar age. 
Periodic augmentation of EE conditions in APP/PS1 mice was associated with a 
deleterious effect on Aβ pathology, and this was associated with further heightened 
levels of corticosterone. In contrast, sustained exposure to regular EE conditions did not 
affect corticosterone levels or amyloid pathology, indicating a potential capacity to 
habituate to long-term changes in the housing environment. While APP/PS1 animals 
housed in EE+ had increased Aβ pathology along with elevated corticosterone, no 
significant behavioural differences were detected on the Y maze test of spatial short-
term memory, or the Barnes maze test of spatial learning and long-term memory 
relative to APP/PS1 mice housed in SH or EE (data not shown). The finding of 
increased pathological burden without cognitive dysfunction may offer support for the 
cognitive reserve theory (Stern, 2012), however following up at later time points when 
neural resources are reduced, would be of interest. 
 
Clinical studies have included reports of people living with AD to generally 
have higher levels of blood cortisol when compared to healthy people (Rasmuson et al., 
2001; Csernansky et al., 2006). Moreover, elevated levels of corticosterone has been 
reported previously in a FAD mouse model (Guo et al., 2012), and Aβ accumulation 
has been associated with increased sensitivity of the HPA axis (Carroll et al., 2011). 
The present study confirms HPA axis dysfunction in an animal model of early AD. 
Several studies have demonstrated using experimental paradigms designed to induce 
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acute stress (e.g. by restraint, loud noise, and bright light) an accelerated onset, or faster 
rate of progression of AD, in FAD mouse models (Dong et al., 2004; Jeong et al., 2006; 
Carroll et al., 2011; Rothman et al., 2012; Baglietto-Vargas et al., 2015). However, in 
the current report, an association was detected between the periodic stimulation 
condition (EE+) and increased corticosterone.  
APP/PS1 mice display Aβ pathology from 4-5 months of age (Jankowsky et al., 
2004), in the hippocampus and neocortex, and associated damage to synapses (Mitew et 
al., 2013), and the hippocampus directly regulates the HPA axis (Herman et al., 1989; 
Jacobson & Sapolsky, 1991; Roozendaal et al., 2001). Green and colleagues (Green et 
al., 2006) speculated that, in AD, glucocorticoid feedback to the hippocampus may be 
lost, leading to an increased stress response. Thus, the increasing levels of 
glucocorticoid may further accelerate pathological processes, acting as a cycle of 
disease process progression.  
Notably, Wt mice did not show increased corticosterone levels after exposure to 
EE+, and, thus, were not stressed by the periodic stimulation of the EE+ condition. In 
contrast, FAD gene-linked deposition of Aβ in the hippocampus and synaptic damage 
in transgenic animals may lead to initial dysregulation of the HPA-axis, which here, 
contributed to a heightened stress response following periodic stimulation in the EE+ 
condition. The periodic stimulation of EE+ may stimulate a harmful cascade, with 
subsequent increases in Aβ leading into an increased stress response to EE+, further 
increasing circulating corticosterone, and further increasing Aβ deposition within the 
hippocampus.  
The findings of this study raises many implications. The finding that elderly 
who enter a nursing home demonstrate more rapid cognitive decline compared to those 
who remain in the community (González-Colaço-Harmand et al., 2014), together with 
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the findings of this study, raise questions into the effect of novel environment exposure 
for people with AD, and how this may alter, or hasten, disease progression. Moreover, 
the findings presented here bring into question cognitive interventions for the elderly, 
and for people living with AD in particular. An intervention aimed at delaying the 
progression of the clinical syndrome, dementia, is urgently needed given the rapidly 
increasing ageing population. As there are no current efficacious pharmacological 
treatments available, non-pharmacological interventions such as cognitive stimulation, 
training, and rehabilitation are of current interest. Such interventions have demonstrated 
various levels of efficacy, although modest-sized effects are typically reported (Choi & 
Twamley, 2013), and it appears that stress levels of the people living with AD 
undergoing such programs has not been examined. Moving forward, this will be an 
important point of investigation, as cognitive interventions for people living with AD 
may have limited beneficial effect, and may potentially induce stress leading to an 
increased progression of the disease process. Likewise, given that Aβ pathology may be 
present in the brain many years before overt dementia symptomology (Braak & Del 
Tredici, 2011), it will be important to examine the role that stress may have in 
facilitating further pathology, and that primary and secondary prevention strategies that 
involve cognitive stimulation are designed to minimise elevated stress. 
Contrary to the hypothesis, the findings presented here demonstrated that a 
complex/novel environment was associated with an increase in Aβ pathological burden. 
Increased levels of the stress hormone, corticosterone, were detected in FAD mice, 
which were further elevated with novel environmental stimulation. The findings of 
Chapter 3 with together with these findings, suggest constant enrichment does not affect 
Aβ pathology, and has some differential beneficial effects on cognitive function. As 
discussed in Chapter 1, the neural mechanisms underlying this association are not well 
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understood, and are seldom investigated, with previous literature focusing on the effect 
on Aβ pathology. The data presented in Chapter 3 suggest EE to be associated with 
some promotion of synaptic connectivity within the hippocampus. However, other 
underlying mechanisms are yet to be elucidated. Emerging evidence suggests 
neuroinflammation to be key contributor to the pathogenesis of AD (Heneka et al., 
2015), and it is not understood how EE may moderate this relationship. Given there are 
benefits of mid-life enrichment, the question was posed of whether late-life enrichment 
would too confer benefit. There is limited literature from both animal and human 
studies surrounding the effect of environmental stimulation in later-life, however, this is 
a critical life-phase to investigate given our rapidly ageing population. Even “normal” 
ageing is accompanied with a reduction in cognitive and mental capacity (e.g. 
Salthouse, 2012). Interventions aimed at protecting cognitive health in ageing are vital, 
as a preservation of cognitive health in ageing is associated with being less likely to 
have a premature death, depend on careers, live in a long-term care setting, or be 
disabled, or hospitalized (McGuire, Ford, & Ajani, 2006). 
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5. The effect of late-life environmental enrichment on 
cognitive function and microglia 
 
5.1 Introduction 
 
As discussed in Chapter 1, the underlying mechanisms leading to a promotion of 
cognitive function by EE in transgenic models of AD pathology and in models of 
healthy ageing, are not well understood. There have been some reports that for healthy 
animals, the benefical effects of EE may involve modulation by the brain’s immune 
cells (Ziv et al., 2006; Choi et al., 2008; Ziv & Schwartz, 2008; Vukovic et al., 2012). 
Microglia are the resident immune cells in the CNS, and constantly survey their 
environment for pathogens, apoptotic cells, and foreign material (Streit et al., 2004). 
There is emerging evidence of microglia being critically involved in the elimination and 
refinement of synaptic connections in the healthy brain. Microglial processes constantly 
contact axons, dendritic spines, and synapses (Stevens et al., 2007; Paolicelli et al., 
2011; Schafer et al., 2012). Recently, microglia have been found to prune synapses, 
where extraneous synapses are removed, and meaningful synapses remain intact 
(Tremblay, Lecours, Samson, Sánchez-Zafra, & Sierra, 2015), a process that continues 
throughout adulthood, and vital to the maintenance of normal brain function (Chen et 
al., 2014). The dynamics of microglial processes have been found to be regulated by 
sensory experience and neuronal activity (Wake, Moorhouse, Jinno, Kohsaka, & 
Nabekura, 2009; Tremblay, Lowery, & Majewska, 2010). Such evidence has led to the 
assumption that microglial contact with synapses may be regulated by complex 
cognitive activity, such as learning and memory processes (Morris, Clark, Zinn, & 
Vissel, 2013) engaged in by EE. 
Microglia, may also have a key role in AD pathogenesis.  Two recent genome-
wide association studies identified that a polymorphism in the triggering receptor 
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expressed in myeloid cells 2 (TREM2) gene, which is associated with decreased 
phagocytosis and an increased pro-inflammatory reactive phenotype of microglia 
(Guerreiro et al., 2013), is associated with a significant increased risk for developing 
AD (Guerreiro et al., 2013; Jonsson et al., 2013). Moreover, microglia frame dense-core 
Aβ plaques (Itagaki et al., 1989), and exhibit an altered phenotype to that of a healthy 
brain, leading to extensive research efforts focused on the role of microglia in AD 
pathogenesis. 
Experimental studies have demonstrated microglia are able to engulf Aβ and 
may act as a primary defence against Aβ accumulation (Prokop, Miller, & Heppner, 
2013). Microglia help to eliminate Aβ through phagocytosis, however, on the other 
hand, facilitate Aβ accumulation through the release of inflammatory factors and 
neurotoxic proteases (Ard, Cole, Wei, Mehrle, & Fratkin, 1996; Majumdar, Capetillo-
Zarate, Cruz, Gouras, & Maxfield, 2011). Microglia secrete neurotoxic molecules, 
which is associated with an exacerbation of Aβ pathology (Combs, Johnson, Cannady, 
Lehman, & Landreth, 1999; Combs, Johnson, Karlo, Cannady, & Landreth, 2000). 
However, microglia also secrete neuroprotective cytokines in the AD brain (Meda et al., 
1999). Whether microglia exert beneficial or detrimental effects in the AD brain, may 
be dependent on the stage of pathology. It has been proposed that microglia are 
beneficial in preventing plaque formation in early stages of disease, however, in later 
stages microglia demonstrate detrimental effects (Prokop et al., 2013). 
Whether microglia serve a protective or detrimental role in AD pathology, may 
be dependent on ageing. Microglia undergo morphologic changes during aging, 
demonstrated by an increased soma size, and shorter, more sparse, and dystrophic 
processes (Streit, 2006; Flanary et al., 2007). These morphological alterations may 
confer functional deficits, as observed in in vivo and in vitro experiments, leading to 
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ineffective phagocytosis of Aβ (Sierra et al., 2007; Floden & Combs, 2011) which may 
provide one mechanism for AD being most typically, a disease of ageing. 
Depending on the immune challenge, microglia exhibit differing phenotypes, 
and orchestrate differing functions within the CNS from inflammatory responses, to 
assisting in brain repair (Southam, Vincent, & Small, 2016). ‘Resting’ microglia are 
morphologically characterized by a small-sized soma, and fine processes that constantly 
survey, sense, and screen their environment (Streit et al., 2004; Nimmerjahn et al., 
2005). In AD, microglia frame dense-core Aβ plaques, and show an altered 
morphology, typically thickened, dystrophic processes, and increased soma size 
(Itagaki et al., 1989), and are observed to have an ‘activated’, pro-inflammatory 
phenotype (Perlmutter et al., 1990). ‘Activated’ microglia clear foreign material 
through cytotoxic and phagocytic mechanisms throughout the CNS (Ransohoff & 
Perry, 2009). However, microglia can exhibit opposing activation states, conferring 
alternate inflammatory responses. Briefly, an M1 state is associated with defence 
against infection and is considered pro-inflammatory. In contrast, an M2 state is 
associated with an attenuation of inflammation (Southam, Vincent, & Small, 2016). 
There has been limited work on how microglia may be involved in the 
relationship between EE, cognitive function, and Aβ neuropathology. One recent study 
(Xu et al., 2016) demonstrated EE-induced morphological and functional alterations to 
microglia in in-vivo and in-vitro experiments, and an associated prevention of an 
inflammatory response to soluble oligomeric Aβ. Notably, these experiments were 
performed on relatively young mice (approximately 3 months of age), and the impact 
that EE may have on senescent microglia in models of healthy ageing, and in AD-
associated pathological ageing, is a concept relatively unexplored. 
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Microglia are critical in both brain injury and in repair, and may, therefore, 
represent an underlying mechanism for the positive functional effects of EE on brain 
function and in resilience to pathology. In the previous Chapters, EE from mid-life up 
until 12 months of age was investigated. In this study, the EE intervention was extended 
to begin at 12 months of age, when APP/PS1 mice have established pathology, and 
terminated at 18 months, in order to examine later-life effects of EE. In this Chapter, 
the influence of EE on microglia was investigated in an APP/PS1 mouse model of 
established Aβ neuropathology. Previous studies on young rodent models have reported 
an increase in microglia quantity following EE. In the current study on a model of 
advanced AD pathology, in which microglia are thought to have detrimental effects, it 
was hypothesised that EE would be associated with a reduction to microglia quantity 
occupying regions important for learning and memory processes, the neocortex and 
hippocampus, and an associated rescue of cognitive function. 
 
5.2 Materials and Methods 
 
5.2.1 Environmental enrichment paradigm 
 
Male transgenic APPswe, PSEN1dE9 (APP/PS1) were used for the present study 
(described in Chapter 2). All animals lived in standard housing (SH) conditions which 
comprised group housing (4-5 mice per 30 x 30 x 14 cm cage), ad Libitum access to 
food and water, an igloo, one small wooden stick and one tissue from weaning until 12 
months of age. From 12 months, APP/PS1 (n = 15) and littermate wildtype control (Wt; 
n = 17) mice were randomly assigned to SH or EE conditions (Late-life EE paradigm, 
described in Chapter 2). Housing conditions were maintained until the 18-month end-
point. 
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5.2.2 Cognitive assessment 
 
The cognitive assessment protocol was followed as for Chapter 2. In this study, 
mice were tested at 12-month baseline (before assignment to differential housing 
conditions), and again at 18 months. All mice were tested on the Y maze task of spatial 
short-term memory, and the Barnes maze test of learning and long-term memory, as 
outlined in Chapters 2 and 3. 
 
5.2.3 Tissue preparation 
 
Following the final day of behavioural testing, mice were weighed and then 
terminally anaesthetized first with gas anaesthesia (isoflurane) followed by sodium 
pentobarbitone (100 mg/kg delivered intraperitoneally). Animals were perfused 
transcardially with 4% paraformaldehyde (PFA) in 0.1M phosphate buffered saline 
(PBS pH 7.4). Brains were then dissected out and transferred to 18% then 30% sucrose 
solutions overnight. Brains for histology were serially sectioned on a cryostat (Leica 
CM 1850) in 40µm coronal sections. Sections used for analysis were from bregma 2.0 - 
-3.0 mm according to the stereotaxic mouse brain atlas (Paxinos & Franklin, 2008). 
  
5.2.4 Immunohistochemistry and histological staining 
 
5.2.4.1 Thioflavin-S 
 
Thioflavin-S (Sigma-Aldrich) staining was performed in order to visualise 
fibrillar and dense-core Aβ plaques (Dickson & Vickers, 2001). Ten serial sections 
evenly spaced throughout the rostrocaudal axis of the brain from bregma 2.0 - -3.0 mm 
according to the stereotaxic mouse brain atlas (Paxinos & Franklin, 2008) were 
incubated in Thioflavin-S and the protocol as outlined in Chapter 2 was followed. 
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5.2.4.2 MOAB-2 
 
The MOAB-2 antibody recognises human fibrillar, as well as unaggregated, 
oligomeric Aβ42 (Youmans et al., 2012). Antigen retrieval by formic acid treatment was 
performed in order to enhance immunoreactivity (Kai et al., 2012). As for Thioflavin-S 
staining, ten sections evenly spaced throughout the rostrocaudal extent of the brain 
(bregma 2.0 - -3.0 mm), and the protocol as outlined in Chapter 2 was followed.  
 
5.2.4.3 Iba1 
 
The Iba1 antibody recognises the ionized calcium binding adaptor molecule 1, 
and immunolabells microglia (Ito et al., 1998). Three sections at approximately bregma 
1.045, -1.855, and -2.88 mm were incubated in formic acid, and immunolabelled with 
the Iba1 antibody following the protocol in Chapter 2. 
 
5.2.5 Image acquisition and analysis 
 
In order to determine microglia density, imaging of Iba1 labelling was 
performed on a Perkin-Elmer Ultraview VOX confocal imaging system with Volocity 
6.3 imaging software. Images of neocortex from the corpus collosum to the rhinal 
fissure and whole hippocampus were acquired using a 20x objective and constant laser 
and exposure settings. In order to determine Aβ plaque load in the neocortex and 
hippocampus, images of Thioflavin-S and MOAB-2 stained brain sections were 
obtained with a Leica DM fluorescence microscope on a 10x objective and NIS 
Elements imaging software. Ten sections evenly spaced from the rostral to caudal 
extent of the neocortex from bregma position 2.0 to -3.0 mm were imaged for MOAB-2 
and Thioflavin-S Aβ plaque load. The left side of the neocortex was imaged from the 
midline to the rhinal fissure of 10 sections per animal. Images of the whole 
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hippocampus were taken between bregma position -1.22 and -2.46 mm of 3-5 sections 
per animal. 
 
5.2.6 Random forest classification for the analysis of histology 
 
Images of brain sections stained with Thioflavin-S, or labelled with MOAB-2, 
and Iba1, were processed to 8-bit greyscale images, and segmented with a custom 
plugin for ImageJ (See Chapter 2).  
 
 
Figure 5.1. Example of random forest segmentation. A One hemisphere of coronal 
mouse brain section immunolabelled with the Iba1 antibody. B Resulting image 
following random forest segmentation. 
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5.3 Results 
 
5.3.1 Body weight 
 
All mice were weighed at the completion of the differential housing period, and 
a one-way ANOVA was conducted in order to determine if there were any significant 
weight differences between groups that could act as a confounding factor. There were 
no significant differences across housing condition or genotype on body weight, F (1, 
29) = 0.27, p = .4. 
 
5.3.2 Y maze 
 
Healthy Wt and APP/PS1 (Tg) mice were tested for spatial short-term memory 
function on the Y maze at 12 months, before being assigned to differential housing. An 
independent t-test demonstrated no significant difference in time spent in the novel arm 
of the maze between genotypes t (30) = 0.16, p = .88. Following the 6-month 
differential housing period, repeat testing was performed, a significant housing x 
genotype interaction was detected, F (1, 28) = 7.79, p = .009. A separate independent t-
test was performed for Tg animals, which showed Tg mice housed in EE spent 
significantly more time in the novel arm of the maze relative to Tg mice housed in SH, t 
(13) = 8.1, p < .001. 
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Figure 5.2. Y maze performance as mean percentage of time spent in the novel arm of 
the maze (± SEM). A 12-month baseline testing revealed no significant difference in 
the percentage of time spent in the novel arm of the maze, t (30) = 0.16, p = .88. B Y 
maze testing following the 6-month differential housing period (18 months of age) 
revealed housing-dependent performance differences for APP/PS1 (Tg) mice, where 
those in EE on average spent more time in the novel arm of the maze, t (13) = 8.1, p < 
.001. 
 
 
5.3.3 Barnes maze  
 
Following the 6-month differential housing period, when animals were 18 
months of age, rate of learning was measured by performance on the Barnes maze over 
7 days. There was no significant learning effect across housing x genotype, F (1, 28) = 
0.05, p = .82. No significant effect of housing x genotype was detected on the long-term 
memory trial of the Barnes maze, F (1, 28) = 2.52, p = .12. However, an independent t-
test demonstrated a significant housing effect for Wt mice, where those housed in EE 
had on average, a significantly reduced latency to reach the escape on the long-term 
memory trial compared to those from SH, t (15) = 3.26, p = .005. 
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Figure 5.3 Barnes maze performance following differential housing, showing mean 
latency to reach the escape box (± SEM). A No significant differences in rate of 
learning were detected between the groups on the 7-day trial Barnes maze, F (1, 28) = 
0.05, p = .82. B Only healthy Wt mice demonstrated performance differences as a 
function of housing, in which Wt mice had on average a significantly lower latency to 
reach the escape compared to Wt mice from SH, t (15) = 3.26, p = .005 
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5.3.4 Aβ load  
 
Fibrillar Aβ plaques were visualised with the Thioflavin-S stain, and no 
significant differences between the housing conditions were detected in Thioflavin-S 
positive plaque load in neocortex, t (13) = 0.73, p = .48, or in hippocampus, t (13) = 
0.81, p = .44. MOAB-2 positive labelling was not significantly different according to 
housing condition in neocortex, t (13) = 0.12, p = .91, or in hippocampus, t (13) = 0.84, 
p = .42. 
 
Table 5.1. Aβ plaque load following late-life differential housing 
 SH 
n = 8 
M (SEM) 
EE 
n = 7 
M (SEM) 
Thioflavin-S (% load neocortex) 
 
3.68 (0.19) 3.67 (0.16) 
Thioflavin-S (% load hippocampus) 
 
2.74 (0.17) 2.98 (0.25) 
MOAB-2 (% load neocortex) 
 
26.43 (1.44) 26.84 (3.35) 
MOAB-2 (% load hippocampus) 16.88 (2.34) 19.29 (1.55) 
 
 
5.3.5 Microglia 
 
 In order to examine the effect of EE and genotype on microglia, brain sections 
were immunolabelled with the antibody Iba1, and the percentage area of labelled 
microglia (% microglia) occupying the neocortex and hippocampus were compared 
across housing and genotype groups. First, independent of housing, there was a 
significant genotype effect on the % microglia, with Tg mice having a greater 
percentage area of microglia within the neocortex (t (8) = 2.95, p = .02), and 
hippocampus (t (8) = 3.93, p = .004), relative to Wts (Figure 5.4). However, overall, no 
significant housing x genotype effects were detected on the percentage area of 
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neocortex occupied by microglia (F (1, 16) = 1.53, p = .23), or that of the hippocampus (F 
(1, 16) = 2.98, p = .10). Of note, is that a significant effect of microglia was detected for 
SH mice between genotypes, where Tg mice had a significantly higher percentage area 
occupied by microglia in neocortex (t (8) = 2.95, p = .02) and hippocampus (t (8) = 3.93, 
p = .004) relative to the Wts. However, this genotype effect was not detected for EE 
mice in the neocortex (t (8) = 1.29, p = .23), or in the hippocampus (t (8) = 1.02, p = .34). 
Although no statistically significant effects were detected across housing conditions, a 
large-sized effect was found for Tg mice between housing conditions in area occupied 
by microglia  in neocortex (d = 0.86) and in hippocampus (d = 1.09), and a small effect 
was detected between the housing conditions for Wt mice in neocortex (d = 0.35), and a 
moderate effect for the hippocampus (d = 0.53) (Figure 5.4). 
 
 
 
Figure 5.4. Percentage area occupied by Iba1 immunolabelled microglia. A APP/PS1 
(SH Tg) mice had an increased percentage area of microglia in neocortex relative to Wt 
(SH), t (8) = 2.95, p = .02. B APP/PS1 (SH Tg) mice had an increased percentage area 
of microglia in hippocampus relative to Wt, t (8) = 3.93, p = .004. 
 
 
*	 **	
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5.3.6 The effect of microglia on cognitive function 
 
There were some noteworthy correlations detected between % microglia and 
cognitive function. Large-sized correlations were detected between percentage area of 
microglia in neocortex and hippocampus and Y maze performance (r = 0.66*; 0.52 
respectively), where a greater percentage of microglia predicted better Y maze 
performance when all groups were included in the analysis. However, considering EE 
has differential effects on the groups, separate analyses were also conducted on each 
housing/genotype group. Wt mice from SH showed a large-sized positive correlation 
between Y maze performance and % microglia (neocortex r = 0.86; hippocampus r = 
0.75). Wt mice from EE also displayed a positive correlation between microglia density 
and Y maze performance (neocortex r = 0.54; hippocampus r = 0.39). In contrast, Tg 
mice from both housing conditions demonstrated negative correlations between Y maze 
performance and % microglia. Tg mice from SH had a moderate correlation between % 
microglia and Y maze performance (neocortex r = -0.33; hippocampus r = -0.48), and 
large-sized correlations were detected for Tg EE mice (neocortex r = -0.70; 
hippocampus r = -0.55). 
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Figure 5.5. Graphical presentation of linear correlations between percentage area 
occupied by microglia and Y maze performance. A Y maze performance and % 
microglia in neocortex for Wts (SH: r = 0.86; EE r = 0.54). B Y maze performance and 
% microglia in neocortex for APP/PS1 mice (SH r = -0.33; EE r = -0.70). C Y maze 
performance and % microglia in hippocampus for Wt mice (SH r = 0.75; r = 0.39). D Y 
maze performance and % microglia in hippocampus for APP/PS1 mice (SH r = -0.48; r 
= -0.55). 
 
 
Given the APP/PS1 mice demonstrated differential Y maze performance as a 
function of housing condition, a linear hierarchical regression analysis was performed 
in order to partial out the influence of housing condition and Aβ load, to investigate the 
underlying relationship between microglia density and Y maze performance. The 
analysis conducted on APP/PS1 mice produced a significant model for predicting Y 
maze performance by housing condition, F (1, 8) = 44.54, p = < .001, with housing 
A	 B	
C	 D	
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condition explaining 84.8% of the variance in Y maze performance. Aβ load was 
entered second into the model (including MOAB-2 and Thioflavin-S load in neocortex 
and hippocampus) and accounted for an additional non-significant 4.5% of the variance 
in Y maze performance above that of housing condition, DF (4, 4) = 0.42, p = .79. 
Microglia (% Iba1labelled microglia in neocortex and hippocampus) was added third 
into the analysis, and accounted for an additional 8.2% of the variance in short-term 
memory function as measured by Y maze performance above housing condition and Aβ 
load, however, this was not statistically significant, DF (2, 2) = 3.22, p = .24. 
A separate linear hierarchical regression analysis was performed for the Wt 
group on long-term memory performance, as performance levels were different 
according to housing condition on this task. Housing condition accounted for 35.9% of 
the variance in long-term memory performance, which was not statistically significant, 
F (1, 8) = 4.47, p = .06. Entering % microglia at the second step of the model, 
accounted for an additional 9.9% of the variance in long-term memory performance on 
the Barnes maze, DF (2, 6) = 0.55, p = .61. 
 
 
 
 
 
 
 
 
 
 
	 126	
5.4 Discussion 
 
 Consistent with the findings presented in Chapter 3 on 12-month old mice, EE 
was not associated with a reduction to Aβ neuropathological burden at 18 months, 
following 6 months of exposure to EE conditions. The findings of Chapter 3 
demonstrated mid-life EE to be associated with improvements to cognitive function 
differentially according to genotype. Late-life EE in the current Chapter was also 
associated with cognitive improvement, which is notable considering the animals lived 
in an environment conferring very minimal stimulation for the first 12 months of life. 
Moreover, late-life EE was associated with a restoration of short-term memory function 
in APP/PS1 mice to the level of healthy Wt mice. The mechanisms underlying the 
association between EE and heightened cognitive function remain to be elucidated, and 
considering microglia are critically involved in repair of the CNS, they are potentially 
key to this association. 
APP/PS1 mice housed in SH demonstrated an increase in the area occupied by 
microglia in both neocortex and hippocampus relative to Wts in SH, an effect reported 
on previously in the human AD brain (McGeer, Itagaki, Tago, & McGeer, 1987; 
Carpenter, Carpenter, & Markesbery, 1993) and in FAD mouse models (Janelsins et al., 
2005; Meyer-Luehmann et al., 2008; Rodríguez, Noristani, & Verkhratsky, 2015). 
Microglia are thought to have a key role in the pathogenesis of AD, and may be one 
critical factor in the link between EE and Aβ pathology. If an EE paradigm promotes 
microglial health, enabling microglia to phagocytose Aβ effectively, this may account 
for a reduction in Aβ load found in some studies  (Lazarov et al., 2005; Costa et al., 
2007; Herring et al., 2011). In the current study, late-life EE had differential, and 
complex effects on microglia.  
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APP/PS1 mice from EE did not show this significant increase in percentage area 
occupied by microglia relative to Wts, as was observed in the SH condition. Previous 
evidence suggests the observed increase in microglia density in AD, is due to an 
altered, enlarged morphology of microglia, as opposed to an increase in proliferation 
(Serrano-Pozo, Gómez-Isla, Growdon, Frosch, & Hyman, 2013). Therefore, the finding 
of APP/PS1 mice from EE having a relatively lower percentage area occupied by 
microglia relative to APP/PS1 mice from SH (large-sized effect), may reflect the EE 
mice having less microglia with an enlarged, pro-inflammatory phenotype (Streit, Xue, 
Tischer, & Bechmann, 2014).   
As APP/PS1 mice demonstrated an increase in short-term memory function 
following EE, a hierarchical regression analysis was conducted in order to examine the 
influence that microglia have in this association. Each measure of Aβ load was entered 
into the model in one step, and accounted for 4.5% of the variance in short-term 
memory function. Microglia (% area) accounted for an additional 8.2% of the variance 
in short-term memory function, which was not statistically significant, although notable 
considering the effect is larger than that of Aβ load. Despite no detection of statistically 
significant effects between microglia and cognitive function, moderate to large effect 
sizes were detected. APP/PS1 mice demonstrated a negative association between area 
occupied by microglia and short-term memory function, that is a greater percentage of 
microglia predicted lower performance levels. This may be reflective of the alterations 
in the phenotype of microglia observed in APP/PS1 mice, from ‘resting’ to an 
‘activated’ state. The negative association between microglia and cognitive function in 
APP/PS1 mice may be due to them possessing a phenotype more representative of a 
reactive inflammatory phenotype, an effect particularly apparent in the SH mice. On the 
other hand, Wt mice demonstrated a positive association between microglia and 
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cognitive function, which is hypothesised to be due to having more “healthy”, resting 
microglia (Streit et al., 2004; Nimmerjahn et al., 2005). Future studies investigating 
microglial phenotypes will address this hypothesis. 
Microglia in the aged or diseased brain switch their phenotype to “primed” in 
which they produce neurotoxic molecules in response to inflammatory signals (Perry, 
Cunningham, & Holmes, 2007). This alteration in phenotype may offer one potential 
mechanism to explain the link between activated microglia and cognitive impairment. 
A reduction in cytokine and chemokine levels, indicative of a reduced pro-
inflammatory phenotype of microglia, has been observed in healthy rats following EE 
(Williamson, Chao, & Bilbo, 2012). In addition, TNFa, a cytokine thought to be a key 
regulator or neuroinflammation (e.g. Holmes et al., 2009), was reported to be decreased 
by EE, and resulted in a neutralising effect on neuroinflammation (Xu et al., 2016). In 
the current study, a positive correlation was observed in Wt animals between microglia 
and memory performance, which may be representative of more microglia exhibiting 
protective functions, such as neutralising inflammation. Alternatively, activated 
microglia such as in AD, secrete interleukin-1β (IL-1β). Elevated levels of IL-1β in the 
hippocampus has been associated with cognitive impairment (Williamson, Sholar, 
Mistry, Smith, & Bilbo, 2011), which may offer a mechanism underlying the negative 
correlation between microglia and memory performance in APP/PS1 mice. 
 In conclusion, the findings of this study suggest that late-life EE is associated 
with increased short-term memory function in APP/PS1 mice independent to alterations 
to Aβ load. A strong, genotype-dependent association between microglia and short-term 
memory function was detected, adding support for the putative relationship between 
microglia and cognitive function. APP/PS1 mice were found to have an increase in 
percentage area occupied by microglia in the hippocampus and neocortex relative to 
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healthy ageing Wt mice, however, EE altered this effect, resulting in no genotype 
differences. This effect was hypothesised to reflect an alteration in phenotype, in which 
APP/PS1 mice from EE may exhibit a less reactive, pro-inflammatory microglial 
phenotype. Overall, microglia appear to play an important role in the association 
between EE and cognitive protection in the presence of Aβ neuropathology. Further 
studies investigating the phenotype of microglia in a FAD model following EE are 
warranted, to further elucidate how the brain’s immune cells modulate stimulation from 
the environment and cognitive protection. 
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6. Final discussion 
 
6.1 Aim 1: Investigate the effect of mid-life environmental enrichment on cognitive 
and synaptic health in healthy and Alzheimer’s disease-associated pathological 
ageing 
 
Key findings 
A wealth of research literature offers support for stimulation from the 
environment beginning in early-life to have beneficial effects on cognitive ageing in 
later-life, potentially by building a reserve against pathological damage, delaying 
cognitive morbidity to later years. However, there have been limited research efforts 
focused on examining cognitive intervention targeted at mid-life.  Moreover, whether 
cognitive stimulation can enhance the compensatory mechanisms that promote synaptic 
connectivity for existing pathology, is unknown.  
The results of this study demonstrated that EE initiated after Aβ plaque 
deposition has begun does not modify the course of subsequent Aβ pathology. Mid-life 
EE was associated with some cognitive protection to short-term memory following 3 
months of EE, in APP/PS1 mice, and an increase in synaptic contacts in the 
hippocampal subregion CA1, as well as elevated levels of hippocampal BDNF. The 
findings regarding APP/PS1 mice are notable, given the lack of stimulation in early-
life, and despite increasing amyloid levels associated with the transgene. Synapse loss 
is a strong correlate of cognitive decline in AD (DeKosky & Scheff, 1990; Terry et al., 
1991; Scheff & Price, 2006; Scheff, Price, Schmitt, Dekosky, & Mufson, 2007; Arendt, 
2009). The findings of this study demonstrate that mid-life environmental stimulation 
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may be an efficacious intervention in early-stage AD by promoting synaptic health and 
delaying cognitive deterioration. In healthy Wt mice, mid-life EE was associated with 
enhanced long-term memory function, and relatively increased levels of inhibitory 
synaptic proteins in the neocortex, and both increased excitatory and decreased 
inhibitory synaptic protein levels in the hippocampus, which may potentially reflect a 
more harmonious balance in the interplay between excitatory and inhibitory activity 
relative to SH or APP/PS1 mice. Overall, the findings of this study demonstrate that 
mid-life EE is associated with the promotion of synaptic and cognitive health in both 
healthy, and AD-associated pathological ageing. 
 
6.2 Aim 2: Examine the effect of complex, novel environmental enrichment on Aβ 
neuropathology 
Key findings 
Given the findings of study 1 (Chapter 3), that mid-life EE was not associated 
with reduced Aβ neuropathology, a ‘dose’ effect of EE on amyloid pathology was 
investigated. This is particularly important to elucidate given the heterogeneity in 
findings from previous reports (Table 1). Furthermore, as acknowledged in Chapter 1, 
there is evidence of stress-hormone levels being associated with Aβ pathology (Dong et 
al., 2004; Jeong et al., 2006; Carroll et al., 2011; Rothman et al., 2012; Baglietto-
Vargas et al., 2015), however, it not a factor controlled for in EE studies on FAD mice. 
The first key finding of this study, was that APP/PS1 mice demonstrated increased 
levels of the stress hormone corticosterone, relative to healthy Wts. When exposed to 
periodic enhanced cognitive stimulation, these animals demonstrated further heightened 
levels of corticosterone as well as increased Aβ pathology. Hence, these findings 
suggest AD may be associated with HPA axis dysfunction, causing stimulating 
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environments to become stress-inducing, leading to a glucocorticoid-pathology cycle 
contributing to further Aβ release and plaque formation. This finding suggests that 
stimulation-based interventions for AD need to be designed to minimise a stress 
response that may exacerbate brain pathology. 
 
6.3 Aim 3: Explore the effect of late-life environmental enrichment on cognitive 
function and microglia 
 
Key findings 
 
Ageing-related alterations to microglia are increasingly recognised as a vital 
contributor to AD pathogenesis. The aim of this study was to assess whether EE 
initiated in later life, and at a stage of advanced Aβ pathology would lead to positive 
cognitive effects as demonstrated in the mid-life cohort, and whether microglia are 
involved in this relationship. The key findings of this study were that late-life EE did 
not alter amyloid pathology, however, was associated with enhanced long-term memory 
performance in Wts and restoration of short-term memory function in APP/PS1 mice. 
APP/PS1 mice in SH demonstrated an increase in the percentage area of neocortex and 
hippocampus occupied by microglia compared to WTs in SH. However, with EE there 
was no genotype effect on microglia, which may reflect an altered phenotype by EE. 
Moreover, there were large-sized correlations between percentage of neocortical and 
hippocampal microglia and cognitive outcomes, and these effects were moderated by 
genotype. The findings of this Chapter suggest that microglia play an important role in 
the association between EE and cognitive protection in the presence of Aβ 
neuropathology, however, further studies are required to clarify this association. 
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6.4 Integration of findings 
 
 The ageing of the global population is accompanied by an increasing and 
substantial social and financial impact of ageing-related diseases that cause dementia, 
for which there is currently no effective treatment or cure (Prince et al., 2015). There is 
a wealth of literature supporting early-life stimulation from the environment being 
beneficial in reducing dementia risk in later-life, however, there is limited research 
evidence for the related benefits of environmental stimulation through mid to late-life. 
Given that compelling evidence suggests that the adult brain has the capacity to 
undergo environment-induced plasticity, and Aβ production can be modulated by 
synaptic activity (Kamenetz et al., 2003), the overarching aim of this thesis was to 
investigate the effect of environmental stimulation from mid to later-life on healthy and 
pathological ageing. 
Early-life EE applied to transgenic FAD models has been associated with 
cognitive improvement, and variable effects on amyloid pathology (Table 1). However, 
the effect of later-life interventions is not well understood. Moreover, while Aβ is a 
hallmark feature of AD, there is an array of molecular and cellular alterations 
characteristic of AD, and so previous studies in this domain that have focused on the 
effect of EE on cognitive function and amyloid pathology are potentially leaving 
underlying neural mechanisms on the positive effects of EE undetected.  
This thesis has offered support for the concept that the ageing brain retains 
capacity for plasticity in non-pathological and pathological conditions. A consistent 
finding from both the mid and late-life EE paradigms was that EE was accompanied by 
an improvement in cognitive function. The finding of cognitive protection afforded by 
EE in early-life paradigms has been widely reported (Nithianantharajah & Hannan, 
2006). However, whether EE has the potential to induce cognitive protection in the 
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ageing brain, has received limited attention. Considering the ageing of populations, and 
the societal demands placed by an increasing number of people experiencing cognitive 
deterioration, the findings presented in this thesis offer encouragement as to the efficacy 
of cognitive engagement therapies for the ageing population.  
One contrasting finding of this thesis was that baseline assessment of short-term 
memory at 6 months of age by the Y maze revealed a deficit in APP/PS1 mice relative 
to Wts (Chapter 3). Despite this, baseline Y maze testing at 12 months of age did not 
show any genotype differences in performance levels (Chapter 5). This may have led to 
differential enrichment effects on cognitive outcome, as the APP/PS1 mice in the mid-
life cohort had a memory deficit to be rescued, where the late-life cohort did not show a 
deficit relative to healthy Wt mice. This may have been due to the Wt mice developing 
an ageing-related decline to short-term memory function due to ageing at 12 months, 
and ‘catching up’ to the level of APP/PS1 mice. However, in both the mid and late-life 
cohort studies, EE exerted differential cognitive effects that were dependent on 
genotype, in which EE was associated with superior long-term memory function in 
healthy Wts, and superior short-term memory function in APP/PS1 mice. The research 
literature on cognitive decline in healthy ageing populations typically shows that short-
memory remains relatively intact (Hedden & Gabrieli, 2004; Salthouse, 2011), whereas 
short-term memory impairment is an early cognitive symptom of AD (Weintraub et al., 
2012). EE may therefore have targeted effects on regions, and subsequently functions, 
of vulnerability. 
The positive effects on cognitive function demonstrated in both the mid-life and 
late-life studies were independent to alterations in Aβ load. Therefore, the findings of 
this thesis suggest that the cognitive benefits afforded by environmental stimulation 
from mid to late-life are not due to a reduction in Aβ neuropathology, as APP/PS1 mice 
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demonstrated a complete restoration of memory function to the level of healthy Wts, 
despite minimal modification of underlying pathology. These findings support the 
cognitive reserve theory, in which individuals who have lived a highly cognitively 
engaging life, are able to withstand a greater neuropathological burden while 
maintaining cognitive function (Stern, 2012). This finding is not in direct contradiction 
to the amyloid cascade hypothesis of AD, in which excess Aβ stimulates a pathological 
cascade leading to the cognitive dysfunction observed in AD (Hardy & Selkoe, 2002). 
This APP/PS1 mouse model possesses Aβ levels 300-500% over endogenous levels 
(Jankowsky et al., 2004), and memory impairment was observed in this model at 6-
month baseline (Chapter 3). However, the FAD model exhibits a mild elevation in 
steady-state Aβ levels (Jankowsky et al., 2005), and the stimulation provided by EE 
appeared to overcome the impairment that may be induced by Aβ pathology, as 
observed in the SH condition across studies. 
While no alterations to Aβ load were detected as a result of EE, the 
complex/novel paradigm (EE+) introduced in mid-life (Chapter 4), was associated with 
increased Aβ deposition in the hippocampus and increased Aβ production in the 
neocortex. The EE+ condition was also associated with increased stress-hormone levels 
in APP/PS1 mice, which appeared to drive the increases in amyloid. Together, these 
findings suggest that a mild form of stimulation from the environment leads to 
improved cognitive function in healthy and pathological ageing, independent of 
alterations in amyloid levels. However, in the case of existing AD-associated 
neuropathology, a more complex form of enrichment that involves exposure to novel 
situations, may increase levels of stress and exacerbate amyloid pathology. 
While EE was not associated with a reduction in Aβ burden, the findings of this 
thesis involved the identification of the promotion of other factors, which potentially 
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mediate the cognitive protection provided by EE. The findings demonstrated an EE-
induced increase in hippocampal BDNF (Chapter 3), which may offer a mechanism for 
improvements in short-term memory function in APP/PS1 EE-exposed mice in both 
mid-life and late-life groups. Compelling evidence indicated that BDNF exerts strong 
pro-survival effects on neurons under pathological conditions, in addition to promoting 
synaptic plasticity and connectivity  (Lu et al., 2013). The APP/PS1 model also 
demonstrated an increase in synaptic density in the hippocampal CA1 subregion, a 
region particularly vulnerable to AD (Scheff et al., 2007), which was likely due to the 
increase in BDNF and associated increase in synaptogenesis. The EE-associated 
promotion of hippocampal BDNF provides a likely driving force underlying the 
increase in synaptic connectivity and restoration of short-term memory function in 
APP/PS1 mice, despite the increasing presence of Aβ pathology. 
Microglia are also thought to support neuronal function by mediating 
neurotrophic factors, including BDNF, in the brain (Elkabes, DiCicco-Bloom, & Black, 
1996). APP/PS1 mice were found to have an increase in microglia density in the 
hippocampus and neocortex relative to healthy ageing Wt mice; EE altered this effect, 
resulting in no genotype differences. This effect was hypothesised to reflect an 
alteration in phenotype, in which APP/PS1 mice from EE may exhibit a less reactive, 
pro-inflammatory microglial phenotype. This evidence together suggests that EE may 
promote microglial health, leading to increased expression of BDNF that results in 
heightened synaptic connectivity, and subsequent protection to hippocampal-dependent 
memory function. These findings suggest that stimulation from the environment can 
enhance the compensatory mechanisms that promote synaptic connectivity for existing 
pathology, allowing for a greater resilience of cognitive function. 
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6.5 Limitations 
 
Much of the understanding that we have of the mechanisms that underlie the 
effects of experience on the human brain, comes from research conducted on animal 
models. In this regard, one central limitation of this thesis is the use of a transgenic 
mouse model of AD. This model possesses mutations in genes involved in familial 
cases of AD, however, familial AD is rare, and the majority of AD cases are sporadic 
(Sherrington et al., 1995; 1996). Moreover, while this transgenic model exhibits some 
cardinal features of the disease, no animal model fully recapitulates the entire disease 
process. For example, this APP/PS1 model does not develop one of the main 
pathological features of AD, neurofibrillary tangles (Garcia-Alloza et al., 2006). While 
the results of thesis should be interpreted with this limitation taken into account, the 
overarching aim of this thesis was to investigate the effects of enrichment on Aβ 
neuropathology and cognitive function. Healthy Wt mice do not develop AD 
sporadically as in human cases, and do not exhibit pathological features of the disease 
(McGowan, Eriksen, & Hutton, 2006). Therefore, this mouse model that does develop 
Aβ neuropathology and cognitive dysfunction (Jankowsky et al. 2004; Garcia-Alloza et 
al. 2006; Vickers et al. 2009) was an appropriate model. In addition, for this thesis, only 
male mice were used. This poses a limitation due to the results potentially only 
transferring to the male population. However, male mice were chosen in these studies, 
as there is an observed increase in Aβ burden in female mice; this association is not 
well understood (Wang et al., 2003), and could have potentially confounded the 
findings of this study. 
It has been argued that many of the benefits of EE are due to enhanced physical 
activity, rather than cognitive stimulation (Pang & Hannan, 2013), which poses a major 
limitation to EE studies. EE involves a variety of sensory, cognitive, and physical 
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activity that cannot be separated in order to investigate the sole effects of a single 
modality. Intrinsically, it is not possible to reproduce the experience of education, 
leisure activity, and occupational attainment in an animal model, when aiming to 
recapitulate the building of cognitive reserve. While some parallels can be drawn 
between EE and cognitive lifestyle in humans, the stimulation provided by EE is not 
completely analogous to the lifetime of experience that contributes to cognitive reserve 
in people. However, even in humans, it is difficult to separate physical activity from 
cognitive stimulation, and other extraneous factors. Therefore, in both human and 
animal studies, it remains to be elucidated what effects cognitive stimulation has on the 
building of cognitive reserve. However, Cracchiolio et al. (2007) aimed to address what 
kind of activity conferred the most benefit in reducing dementia risk. It was found that 
“complete” housing encompassing physical, cognitive, and social stimulation, conferred 
the most cognitive benefit as compared to only social or physical exercise conditions.  
 Much of the data generated in this thesis showed moderate variability; it is 
plausible that some mice may have “engaged” more in the stimulating environment 
than others, which could potentially result in greater neural and functional gains. Future 
studies would benefit from recording activity in EE, which would allow the individual 
engagement of mice to be tracked. Subsequently, it could be determined whether 
individual patterns of activity may modulate the effects of enrichment on the brain and 
cognitive function. In addition, the efficacy of the EE paradigms on functional outcome 
was assessed by cognitive testing using the Y maze and the Barnes maze. Cognitive 
testing on mouse models is highly variable (Stewart et al., 2011), and the Y maze, while 
commonly used to assess spatial memory function (Webster et al., 2014), is not highly 
sensitive to subtle cognitive deficit (Stewart et al., 2011). Therefore, future research 
should use more sensitive measures, such as the Radial Arm Maze in detecting 
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cognitive dysfunction in animal models of early-stage disease (Stewart et al., 2011).  
Moreover, group housing of mice tends to generate a dominance hierarchy, which first, 
may have altered the level of engagement in EE. Second, EE has been associated with a 
loss in stability of the hierarchy (Haemisch, Voss, & Gärtner, 1994), which also could 
have potentially confounded findings. 
 While employing an EE paradigm with animal models poses inherent 
limitations, the effect of cognitive stimulation on the neural system could not have been 
investigated in a living human sample. Furthermore, an EE paradigm offers a controlled 
environment, allowing for genetic and environmental factors to be carefully controlled 
for. This is in direct contrast to human populations studies, in which there is an array of 
extraneous factors that are challenging to control for, potentially confounding findings. 
 
6.6 Implications 
 
The study of an EE paradigm in healthy and pathological ageing has allowed for 
some mechanistic insight into how stimulation from the environment might modulate 
the ageing nervous system and the neural response to AD pathogenesis. With further 
investigation, key molecular pathways stimulated by EE may be identified, allowing for 
the identification of therapeutic targets that could be promoted exogenously through a 
treatment strategy that parallels EE, or through the development of new drugs that 
could mimic the beneficial effects of EE, or ‘enviromimetics’ (Nithianantharajah & 
Hannan, 2006). In this thesis, an EE-associated increase in hippocampal BDNF in 
APP/PS1 mice was identified, which may have led to the increase in synaptic density 
and short-term memory function demonstrated in both mid and late-life cohorts. BDNF 
may therefore offer an encouraging molecular target for the promotion of cognitive 
health in healthy and pathological ageing. 
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The findings of this thesis demonstrate that the ageing neural system is capable 
of undergoing plastic alterations in response to stimulation from the environment, in 
both non-pathological and pathological conditions. Perhaps most remarkably, even in 
the presence of neuropathology, EE can induce compensatory mechanisms promoting 
synaptic connectivity and cognitive restoration. EE is a non-invasive therapy that 
confers powerful benefits, and has the potential to transfer into human interventions for 
pathological and non-pathological ageing. 
The findings of this thesis also led to the identification of an abnormal stress-
response in APP/PS1 mice that was associated with exacerbated pathology. This 
finding raises implications as to the importance of assessing forms of cognitive 
stimulation therapies for their intensiveness and potential to cause frustration and stress, 
particularly for people with existing dementia due to AD. Moreover, introducing stress-
reduction strategies for people living with AD, may offer an efficacious strategy for 
slowing disease process progression. 
 
6.7 Future research 
 
Further studies would benefit from tying these findings together, to more fully 
elucidate the underlying mechanisms that mediate the effect of EE on cognitive 
function in models of ageing and AD-neuropathology. APP/PS1 mice demonstrated 
signs of a disruption to the balance between synaptic inhibition and excitation (Chapter 
3). Therefore, it would be important to investigate microglia in the mid-life cohort. 
Activated microglia secrete interleukin-1β (IL-1β), with elevated levels in the 
hippocampus reported to be associated with cognitive impairment (Williamson et al., 
2011), and with the disruption of the normal balance between synaptic excitation and 
inhibition (Patterson, 2015). Furthermore, one of the key mechanisms by which the 
brain regulates immune activity is via the HPA axis. Glucocorticoids can have opposing 
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effects on microglial activity (Ashwell, Lu, & Vacchio, 2000), which may have 
contributed to the exacerbation of Aβ detected in mice exposed to the EE+ condition 
(Chapter 4). 
The findings presented in Chapter 4, of an elevated stress-response to 
complexity and novelty, and associated exacerbated pathology, has potential for a 
human translation study. Cognitive stimulation therapies have demonstrated variable 
effects on people living with dementia, and are often assumed to at least do no harm 
(Choi & Twamley, 2013). Despite this, the effects on stress-hormone levels in people 
living with dementia have not been reported. Future studies on cognitive interventions 
for people living with dementia should also analyse levels of stress, as this may hasten 
disease progression. 
 
6.8 Conclusion 
 
 In conclusion, EE paradigms introduced through mid to later-life for both non-
pathological and pathological ageing, are associated with some level of cognitive 
enhancement and/or resilience. The findings of this thesis suggest the protective effect 
of EE on cognitive function in a transgenic model of AD pathology, relies on an 
enhancement of synaptic connectivity and promotion of neural plasticity, as cognitive 
protection was observed with no evidence of an attenuation to existing Aβ 
neuropathology. EE is a non-invasive therapy, that confers many powerful benefits to 
the neural system in both ageing and pathological contexts. The EE paradigm has the 
potential to lead to a new approach to cognitive and/or behavioural therapies, or the 
development of new pharmacological treatments, for the treatment of ageing-associated 
cognitive decline and dementia. 
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